{ "disease": "acute-myeloid-leukemia", "label": "Acute myeloid leukemia", "url": "https://usebiotransfer.org/disease/acute-myeloid-leukemia/", "built": "2026-09-11", "facts_hash": { "answers": "1ea2e9239165", "targets": "b3cdf96f06f6" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-11", "trials": "2026-09-11" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "FLT3", "ensembl": "ENSG00000122025", "n_drug_entries": 45, "n_distinct_drugs": 39, "drugs": { "4SC-203": "PHASE_1", "AKN-028": "PHASE_1_2", "AMG553": "PHASE_1", "AMUVATINIB": "PHASE_2", "AS-602868": "PHASE_1", "AT-9283": "PHASE_3", "C-1311": "PHASE_2", "CDX-301": "PHASE_2", "CEP-2563": "PHASE_1", "CM-082": "PHASE_2", "CRENOLANIB": "PHASE_3", "CT-1578": "PHASE_1", "DOVITINIB": "PHASE_3", "ENMD-2076": "PHASE_2", "ENMD-981693": "PHASE_2", "FAMITINIB": "PHASE_3", "FEDRATINIB": "APPROVAL", "FF-10101": "PHASE_1_2", "FLYSYN": "PHASE_1_2", "FORETINIB": "PHASE_2", "GILTERITINIB": "APPROVAL", "IMC-EB10": "PHASE_1", "KW-2449": "PHASE_1", "LESTAURTINIB": "APPROVAL", "LINIFANIB": "PHASE_3", "MIDOSTAURIN": "APPROVAL", "NINGETINIB": "PHASE_2", "PACRITINIB": "APPROVAL", "PEXIDARTINIB": "APPROVAL", "QUIZARTINIB": "APPROVAL", "RG-1530": "PHASE_1", "RUSERONTINIB": "PHASE_3", "SORAFENIB": "APPROVAL", "SU-014813": "PHASE_2", "SUNITINIB": "APPROVAL", "SUNITINIB MALATE": "APPROVAL", "TANDUTINIB": "PHASE_2", "XL-999": "PHASE_2", "ZOTIRACICLIB": "PHASE_1_2" }, "approved": [ "FEDRATINIB", "GILTERITINIB", "LESTAURTINIB", "MIDOSTAURIN", "PACRITINIB", "PEXIDARTINIB", "QUIZARTINIB", "SORAFENIB", "SUNITINIB", "SUNITINIB MALATE" ], "n_approved": 10, "approved_for": { "FEDRATINIB": [ "myeloproliferative disorder", "primary myelofibrosis", "myelofibrosis", "acquired polycythemia vera" ], "GILTERITINIB": [ "acute myeloid leukemia", "myeloid leukemia", "acute myeloid leukemia by FAB classification" ], "LESTAURTINIB": [ "acute myeloid leukemia by FAB classification" ], "MIDOSTAURIN": [ "mast cell leukemia", "mastocytosis", "acute myeloid leukemia by FAB classification", "systemic mastocytosis", "acute myeloid leukemia" ], "PACRITINIB": [ "primary myelofibrosis", "acquired polycythemia vera", "myelofibrosis" ], "PEXIDARTINIB": [ "tenosynovial giant cell tumor", "tenosynovial giant cell tumor, diffuse type" ], "QUIZARTINIB": [ "acute myeloid leukemia", "myeloid leukemia", "acute myeloid leukemia by FAB classification" ], "SORAFENIB": [ "renal cell carcinoma", "thyroid gland carcinoma", "hepatocellular carcinoma" ], "SUNITINIB": [ "gastrointestinal stromal tumor", "renal cell carcinoma", "neuroendocrine neoplasm" ], "SUNITINIB MALATE": [ "renal cell carcinoma", "gastrointestinal stromal tumor", "neuroendocrine neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Phase 1 Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "NPM1", "ensembl": "ENSG00000181163", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "CERITINIB": "APPROVAL", "CRIZOTINIB": "APPROVAL" }, "approved": [ "CERITINIB", "CRIZOTINIB" ], "n_approved": 2, "approved_for": { "CERITINIB": [ "non-small cell lung carcinoma" ], "CRIZOTINIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "IDH1", "ensembl": "ENSG00000138413", "n_drug_entries": 8, "n_distinct_drugs": 7, "drugs": { "BAY1436032": "PHASE_1", "DS-1001B": "PHASE_2", "IDH305": "PHASE_2", "IVOSIDENIB": "APPROVAL", "OLUTASIDENIB": "APPROVAL", "SAFUSIDENIB": "PHASE_3", "VORASIDENIB": "APPROVAL" }, "approved": [ "IVOSIDENIB", "OLUTASIDENIB", "VORASIDENIB" ], "n_approved": 3, "approved_for": { "IVOSIDENIB": [ "acute myeloid leukemia", "acute myeloid leukemia by FAB classification", "cholangiocarcinoma" ], "OLUTASIDENIB": [ "acute myeloid leukemia by FAB classification", "acute myeloid leukemia" ], "VORASIDENIB": [ "astrocytoma (excluding glioblastoma)", "oligodendroglioma", "glioma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "IDH2", "ensembl": "ENSG00000182054", "n_drug_entries": 4, "n_distinct_drugs": 2, "drugs": { "ENASIDENIB": "APPROVAL", "VORASIDENIB": "APPROVAL" }, "approved": [ "ENASIDENIB", "VORASIDENIB" ], "n_approved": 2, "approved_for": { "ENASIDENIB": [ "acute myeloid leukemia by FAB classification", "acute myeloid leukemia" ], "VORASIDENIB": [ "astrocytoma (excluding glioblastoma)", "oligodendroglioma", "glioma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "KMT2A", "ensembl": "ENSG00000118058", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "REVUMENIB": "PHASE_3", "REVUMENIB SESQUIFUMARATE": "PHASE_1_2" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Phase 1 Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "MEN1", "ensembl": "ENSG00000133895", "n_drug_entries": 3, "n_distinct_drugs": 2, "drugs": { "REVUMENIB": "APPROVAL", "REVUMENIB SESQUIFUMARATE": "PHASE_1_2" }, "approved": [ "REVUMENIB" ], "n_approved": 1, "approved_for": { "REVUMENIB": [ "leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Phase 1 Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "DNMT3A", "ensembl": "ENSG00000119772", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "AZACITIDINE": "APPROVAL", "DECITABINE": "APPROVAL" }, "approved": [ "AZACITIDINE", "DECITABINE" ], "n_approved": 2, "approved_for": { "AZACITIDINE": [ "myelodysplastic syndrome", "chronic myelomonocytic leukemia", "myelodysplastic syndrome with excess blasts", "acute myeloid leukemia" ], "DECITABINE": [ "myelodysplastic syndrome with excess blasts", "myelodysplastic syndrome", "chronic myelomonocytic leukemia", "anemia", "myeloid leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "BCL2", "ensembl": "ENSG00000171791", "n_drug_entries": 7, "n_distinct_drugs": 5, "drugs": { "APG-2575": "PHASE_3", "NAVITOCLAX": "APPROVAL", "OBATOCLAX": "PHASE_3", "OBLIMERSEN": "APPROVAL", "VENETOCLAX": "APPROVAL" }, "approved": [ "NAVITOCLAX", "OBLIMERSEN", "VENETOCLAX" ], "n_approved": 3, "approved_for": { "NAVITOCLAX": [], "OBLIMERSEN": [], "VENETOCLAX": [ "B-cell chronic lymphocytic leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "CD33", "ensembl": "ENSG00000105383", "n_drug_entries": 5, "n_distinct_drugs": 5, "drugs": { "AVE-9633": "PHASE_1", "GEMTUZUMAB": "PHASE_2", "GEMTUZUMAB OZOGAMICIN": "APPROVAL", "LINTUZUMAB": "PHASE_3", "ONCOLYSIN M": "PHASE_1" }, "approved": [ "GEMTUZUMAB OZOGAMICIN" ], "n_approved": 1, "approved_for": { "GEMTUZUMAB OZOGAMICIN": [ "myeloid leukemia", "acute myeloid leukemia by FAB classification", "acute myeloid leukemia", "acute promyelocytic leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "IL3RA", "ensembl": "ENSG00000185291", "n_drug_entries": 5, "n_distinct_drugs": 5, "drugs": { "CSL-360": "PHASE_1", "FLOTETUZUMAB": "PHASE_2", "PIVEKIMAB SUNIRINE": "PHASE_2_3", "TAGRAXOFUSP": "APPROVAL", "TALACOTUZUMAB": "PHASE_2_3" }, "approved": [ "TAGRAXOFUSP" ], "n_approved": 1, "approved_for": { "TAGRAXOFUSP": [ "acute myeloid leukemia by FAB classification", "CD4+/CD56+ hematodermic neoplasm", "lymphoma", "acute myeloid leukemia" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "KIT", "ensembl": "ENSG00000157404", "n_drug_entries": 38, "n_distinct_drugs": 33, "drugs": { "AMUVATINIB": "PHASE_2", "AVAPRITINIB": "APPROVAL", "BRIQUILIMAB": "PHASE_2", "CATEQUENTINIB": "PHASE_3", "CEDIRANIB": "APPROVAL", "CM-082": "PHASE_2", "DASATINIB": "APPROVAL", "DOVITINIB": "PHASE_3", "ENMD-2076": "PHASE_2", "FAMITINIB": "PHASE_3", "FORETINIB": "PHASE_2", "IMATINIB": "APPROVAL", "MASITINIB": "APPROVAL", "MIDOSTAURIN": "APPROVAL", "MOTESANIB": "PHASE_3", "OSI-930": "PHASE_1", "PAZOPANIB": "APPROVAL", "PEXIDARTINIB": "APPROVAL", "QUIZARTINIB": "APPROVAL", "REGORAFENIB": "APPROVAL", "RIPRETINIB": "APPROVAL", "SEMAXANIB": "PHASE_3", "SERALUTINIB": "PHASE_3", "SORAFENIB": "APPROVAL", "SU-014813": "PHASE_2", "SUNITINIB": "APPROVAL", "SUNITINIB MALATE": "APPROVAL", "TANDUTINIB": "PHASE_2", "TELATINIB": "PHASE_2", "TIVOZANIB": "APPROVAL", "VATALANIB": "PHASE_3", "XL-820": "PHASE_2", "XL-999": "PHASE_2" }, "approved": [ "AVAPRITINIB", "CEDIRANIB", "DASATINIB", "IMATINIB", "MASITINIB", "MIDOSTAURIN", "PAZOPANIB", "PEXIDARTINIB", "QUIZARTINIB", "REGORAFENIB", "RIPRETINIB", "SORAFENIB", "SUNITINIB", "SUNITINIB MALATE", "TIVOZANIB" ], "n_approved": 15, "approved_for": { "AVAPRITINIB": [ "gastrointestinal stromal tumor" ], "CEDIRANIB": [], "DASATINIB": [ "chronic myelogenous leukemia, BCR-ABL1 positive", "acute lymphoblastic leukemia", "blast phase chronic myelogenous leukemia, BCR-ABL1 positive", "lymphoid leukemia" ], "IMATINIB": [ "chronic myelogenous leukemia, BCR-ABL1 positive", "myelodysplastic/myeloproliferative disease", "gastrointestinal stromal tumor", "dermatofibrosarcoma protuberans", "blast phase chronic myelogenous leukemia, BCR-ABL1 positive", "B-cell acute lymphoblastic leukemia", "hypereosinophilic syndrome" ], "MASITINIB": [], "MIDOSTAURIN": [ "mast cell leukemia", "mastocytosis", "acute myeloid leukemia by FAB classification", "systemic mastocytosis", "acute myeloid leukemia" ], "PAZOPANIB": [ "renal cell carcinoma", "soft tissue sarcoma", "sarcoma" ], "PEXIDARTINIB": [ "tenosynovial giant cell tumor", "tenosynovial giant cell tumor, diffuse type" ], "QUIZARTINIB": [ "acute myeloid leukemia by FAB classification" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "RIPRETINIB": [ "gastrointestinal stromal tumor" ], "SORAFENIB": [ "renal cell carcinoma", "hepatocellular carcinoma", "thyroid gland carcinoma" ], "SUNITINIB": [ "gastrointestinal stromal tumor", "renal cell carcinoma", "neuroendocrine neoplasm" ], "SUNITINIB MALATE": [ "renal cell carcinoma", "gastrointestinal stromal tumor", "neuroendocrine neoplasm" ], "TIVOZANIB": [ "renal cell carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Phase 1 Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CEBPA", "ensembl": "ENSG00000245848", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] } ], "trials": { "by_antigen": { "CD33": { "n": 181, "n_observational": 15, "n_active": 45, "n_withdrawn": 6, "trials": [ { "nct": "NCT00801489", "title": "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01409161", "title": "Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589729", "title": "Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737955", "title": "Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04050280", "title": "CLAG-GO for Patients With Persistent, Relapsed or Refractory AML", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04168502", "title": "Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML", "status": "RECRUITING", "last_update": "2024-11-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385290", "title": "Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)", "status": "RECRUITING", "last_update": "2025-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04793919", "title": "Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia", "status": "RECRUITING", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05105152", "title": "PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183035", "title": "Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05558124", "title": "CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672147", "title": "CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904106", "title": "Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05945849", "title": "CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994690", "title": "CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients", "status": "RECRUITING", "last_update": "2025-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06326021", "title": "Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419634", "title": "Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06420063", "title": "Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448013", "title": "A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06594445", "title": "HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762132", "title": "A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-01-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06917911", "title": "Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198867", "title": "A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07270978", "title": "Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS", "status": "RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07668557", "title": "Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002609", "title": "Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002800", "title": "Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002890", "title": "Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2013-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003131", "title": "CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse", "status": "COMPLETED", "last_update": "2012-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003407", "title": "Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML", "status": "WITHDRAWN", "last_update": "2023-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003673", "title": "CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse", "status": "COMPLETED", "last_update": "2012-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005962", "title": "Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006045", "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006084", "title": "Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006122", "title": "Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006265", "title": "Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00008151", "title": "Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2010-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00014495", "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer", "status": "COMPLETED", "last_update": "2016-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00016159", "title": "Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017589", "title": "Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028899", "title": "Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2014-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00037583", "title": "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2009-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00037596", "title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038051", "title": "Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies", "status": "COMPLETED", "last_update": "2013-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038805", "title": "Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2018-10-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038831", "title": "Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00044733", "title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant", "status": "COMPLETED", "last_update": "2006-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049179", "title": "S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2015-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049517", "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00052299", "title": "Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00070174", "title": "Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy", "status": "COMPLETED", "last_update": "2014-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00077116", "title": "Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085709", "title": "S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089050", "title": "Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2011-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00091234", "title": "Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2012-07-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00121303", "title": "Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2016-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00136084", "title": "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia", "status": "COMPLETED", "last_update": "2012-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143975", "title": "Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)", "status": "COMPLETED", "last_update": "2010-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00195000", "title": "Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00233909", "title": "A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2008-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274781", "title": "Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2015-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00283114", "title": "A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2014-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00304447", "title": "Study Evaluating the Effect of Corticosteroids on Mylotarg\u00ae Infusion-Related Adverse Events in Patients With Leukemia", "status": "COMPLETED", "last_update": "2009-07-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372593", "title": "Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2021-03-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00413166", "title": "All-trans Retinoic Acid, and Arsenic +/- Idarubicin", "status": "COMPLETED", "last_update": "2019-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00454480", "title": "Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-08-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00460447", "title": "Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation", "status": "UNKNOWN", "last_update": "2007-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00476541", "title": "NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492856", "title": "S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528333", "title": "A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML", "status": "COMPLETED", "last_update": "2015-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00543972", "title": "Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2009-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551460", "title": "S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577694", "title": "Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2015-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00658814", "title": "Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00660036", "title": "Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2016-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00669890", "title": "Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML", "status": "TERMINATED", "last_update": "2015-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00673153", "title": "Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2017-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00766116", "title": "Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00798213", "title": "SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)", "status": "TERMINATED", "last_update": "2015-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00860639", "title": "Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk", "status": "COMPLETED", "last_update": "2017-01-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00893399", "title": "Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation", "status": "COMPLETED", "last_update": "2023-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00895934", "title": "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML", "status": "COMPLETED", "last_update": "2019-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00909168", "title": "Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2014-05-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00927498", "title": "A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old", "status": "COMPLETED", "last_update": "2013-07-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00962767", "title": "Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission", "status": "COMPLETED", "last_update": "2009-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968071", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01019317", "title": "Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2016-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01020539", "title": "Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia", "status": "COMPLETED", "last_update": "2021-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01039363", "title": "Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2009-12-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01041040", "title": "LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2013-07-31", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01548911", "title": "Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2018-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01698879", "title": "Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment", "status": "COMPLETED", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723657", "title": "Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2012-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864902", "title": "Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33", "status": "UNKNOWN", "last_update": "2016-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01902329", "title": "A Safety Study of SGN-CD33A in AML Patients", "status": "COMPLETED", "last_update": "2018-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117297", "title": "SCT Plus Immune Therapy in Average Risk AML/MDS", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02182596", "title": "DNR and AraC Combined to Fractionated Mylotarg\u00ae in Patients With First Relapse of AML", "status": "COMPLETED", "last_update": "2014-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02221310", "title": "Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272478", "title": "Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations", "status": "UNKNOWN", "last_update": "2020-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02326584", "title": "A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML", "status": "COMPLETED", "last_update": "2018-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02473146", "title": "Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4", "status": "COMPLETED", "last_update": "2024-02-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520427", "title": "A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02575963", "title": "Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients", "status": "COMPLETED", "last_update": "2023-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02614560", "title": "A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients", "status": "TERMINATED", "last_update": "2019-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02674763", "title": "Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02724163", "title": "International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02785900", "title": "Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-12-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02799680", "title": "Allogeneic CART-33 for Relapsed/Refractory CD33+ AML", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02944162", "title": "CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126864", "title": "Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2019-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03144245", "title": "Study of AMV564 in Patients With AML", "status": "COMPLETED", "last_update": "2021-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207191", "title": "Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2022-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03214666", "title": "GTB-3550 Tri-Specific Killer Engager (TriKE\u00ae) for High Risk Hematological Malignancies", "status": "TERMINATED", "last_update": "2022-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222674", "title": "Multi-CAR T Cell Therapy for Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03374332", "title": "Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03390296", "title": "OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03441048", "title": "Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-10-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473457", "title": "CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-09-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03516760", "title": "Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2022-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03531918", "title": "Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm", "status": "COMPLETED", "last_update": "2023-08-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568994", "title": "Atovaquone (Mepron\u00ae) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03672539", "title": "Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03705858", "title": "Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2019-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727750", "title": "Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML", "status": "COMPLETED", "last_update": "2022-03-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03795779", "title": "CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2021-05-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839446", "title": "Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy", "status": "COMPLETED", "last_update": "2025-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03848754", "title": "Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03867682", "title": "Venetoclax and Lintuzumab-Ac225 in AML Patients", "status": "UNKNOWN", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878927", "title": "CPX-351+GO in Subjects 55 Years Old, or Older, With AML", "status": "TERMINATED", "last_update": "2023-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03900949", "title": "Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03904251", "title": "CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915379", "title": "A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03927261", "title": "PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03932318", "title": "Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients", "status": "WITHDRAWN", "last_update": "2023-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03971799", "title": "Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010877", "title": "Multiple CAR-T Cell Therapy Targeting AML", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04070768", "title": "Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04093505", "title": "Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)", "status": "TERMINATED", "last_update": "2022-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156256", "title": "CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173585", "title": "TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib", "status": "COMPLETED", "last_update": "2023-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04207190", "title": "Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04326439", "title": "AflacLL1901 (CHOA-AML)", "status": "TERMINATED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04478695", "title": "Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04835519", "title": "Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04849910", "title": "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS", "status": "TERMINATED", "last_update": "2025-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04915612", "title": "Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008575", "title": "Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016063", "title": "Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077423", "title": "A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-05-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05199051", "title": "A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215015", "title": "Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-01-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05248685", "title": "Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2025-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445765", "title": "Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467254", "title": "Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05473221", "title": "Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05599360", "title": "Vyxeos for Induction of Low- or Intermediate-risk.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601466", "title": "Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654779", "title": "CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05662904", "title": "Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665075", "title": "Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-01-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673057", "title": "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05716009", "title": "Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML", "status": "TERMINATED", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943314", "title": "Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2023-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955261", "title": "A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05984199", "title": "Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant", "status": "TERMINATED", "last_update": "2025-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05987696", "title": "Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05995041", "title": "Universal CAR-T Cells Targeting AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06325748", "title": "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06367673", "title": "Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2024-04-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06802523", "title": "Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07026942", "title": "Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07370064", "title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07538713", "title": "Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07676006", "title": "A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 36, "n_observational": 1, "n_active": 16, "n_withdrawn": 2, "trials": [ { "nct": "NCT05105152", "title": "PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05672147", "title": "CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05945849", "title": "CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06326021", "title": "Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06420063", "title": "Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762132", "title": "A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-01-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07668557", "title": "Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864902", "title": "Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33", "status": "UNKNOWN", "last_update": "2016-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02799680", "title": "Allogeneic CART-33 for Relapsed/Refractory CD33+ AML", "status": "UNKNOWN", "last_update": "2016-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02944162", "title": "CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126864", "title": "Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2019-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222674", "title": "Multi-CAR T Cell Therapy for Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473457", "title": "CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-09-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03927261", "title": "PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03971799", "title": "Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010877", "title": "Multiple CAR-T Cell Therapy Targeting AML", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04070768", "title": "Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04835519", "title": "Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008575", "title": "Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016063", "title": "Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05248685", "title": "Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2025-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445765", "title": "Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467254", "title": "Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05473221", "title": "Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601466", "title": "Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665075", "title": "Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-01-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943314", "title": "Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2023-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05984199", "title": "Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant", "status": "TERMINATED", "last_update": "2025-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05987696", "title": "Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05995041", "title": "Universal CAR-T Cells Targeting AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06325748", "title": "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06367673", "title": "Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2024-04-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07370064", "title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07538713", "title": "Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07676006", "title": "A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD33", "gemtuzumab", "Mylotarg", "lintuzumab", "vadastuximab", "AMG 330" ] }, "CD123": { "n": 78, "n_observational": 1, "n_active": 36, "n_withdrawn": 6, "trials": [ { "nct": "NCT03113643", "title": "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04318678", "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05442216", "title": "Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05949125", "title": "Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034275", "title": "Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies", "status": "RECRUITING", "last_update": "2024-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06125652", "title": "Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)", "status": "RECRUITING", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06201247", "title": "Off-the-shelf CD123 CAR-NK for R/R AML", "status": "RECRUITING", "last_update": "2025-03-11", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06420063", "title": "Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498973", "title": "Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561152", "title": "Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06634394", "title": "APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2025-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690827", "title": "Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06765876", "title": "CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06835140", "title": "CD123-CD16-NK Cells Immunotherapy for AML", "status": "RECRUITING", "last_update": "2025-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07148180", "title": "A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07306832", "title": "A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07464951", "title": "CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07581002", "title": "A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397579", "title": "DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2019-04-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01632852", "title": "A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission", "status": "COMPLETED", "last_update": "2015-10-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02113982", "title": "Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02152956", "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02159495", "title": "Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02270463", "title": "SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission", "status": "TERMINATED", "last_update": "2024-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02472145", "title": "An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2019-03-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02623582", "title": "CD123 Redirected Autologous T Cells for AML", "status": "TERMINATED", "last_update": "2017-10-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02715011", "title": "Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2021-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02730312", "title": "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies", "status": "COMPLETED", "last_update": "2022-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02848248", "title": "A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992860", "title": "Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY", "status": "TERMINATED", "last_update": "2018-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03114670", "title": "Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT", "status": "UNKNOWN", "last_update": "2017-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190278", "title": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03203369", "title": "Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN", "status": "TERMINATED", "last_update": "2019-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222674", "title": "Multi-CAR T Cell Therapy for Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386513", "title": "Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473457", "title": "CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-09-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556982", "title": "CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia\uff08AML\uff09", "status": "UNKNOWN", "last_update": "2018-06-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631576", "title": "CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)", "status": "UNKNOWN", "last_update": "2020-01-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03647800", "title": "Study of APVO436 in Patients With AML or MDS", "status": "UNKNOWN", "last_update": "2022-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03672851", "title": "Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia", "status": "TERMINATED", "last_update": "2019-09-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739606", "title": "Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer", "status": "WITHDRAWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766126", "title": "Lentivirally Redirected CD123 Autologous T Cells in AML", "status": "TERMINATED", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03796390", "title": "Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia", "status": "UNKNOWN", "last_update": "2019-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010877", "title": "Multiple CAR-T Cell Therapy Targeting AML", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014881", "title": "Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.", "status": "UNKNOWN", "last_update": "2019-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086264", "title": "IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04106076", "title": "Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2020-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04156256", "title": "CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2019-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158739", "title": "Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230265", "title": "Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04265963", "title": "CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04272125", "title": "Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04342962", "title": "Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04582864", "title": "Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)", "status": "TERMINATED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599543", "title": "IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2020-10-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04678336", "title": "CD123 Redirected T Cells for AML in Pediatric Subjects", "status": "TERMINATED", "last_update": "2025-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04681105", "title": "Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973618", "title": "Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML", "status": "WITHDRAWN", "last_update": "2021-12-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05233618", "title": "Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05320380", "title": "A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat", "status": "WITHDRAWN", "last_update": "2023-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05362773", "title": "A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05457010", "title": "Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05506956", "title": "Post-transplant Flotetuzumab for AML", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513612", "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies", "status": "WITHDRAWN", "last_update": "2023-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574608", "title": "Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-04-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673057", "title": "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05716009", "title": "Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML", "status": "TERMINATED", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05720988", "title": "Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05817058", "title": "First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2025-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05995041", "title": "Universal CAR-T Cells Targeting AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006403", "title": "Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034470", "title": "Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06359002", "title": "Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06456463", "title": "A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508489", "title": "A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies", "status": "TERMINATED", "last_update": "2025-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07201727", "title": "CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07809906", "title": "Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 29, "n_observational": 0, "n_active": 12, "n_withdrawn": 2, "trials": [ { "nct": "NCT04318678", "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06125652", "title": "Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)", "status": "RECRUITING", "last_update": "2023-11-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06420063", "title": "Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06765876", "title": "CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06835140", "title": "CD123-CD16-NK Cells Immunotherapy for AML", "status": "RECRUITING", "last_update": "2025-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07464951", "title": "CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02623582", "title": "CD123 Redirected Autologous T Cells for AML", "status": "TERMINATED", "last_update": "2017-10-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03114670", "title": "Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT", "status": "UNKNOWN", "last_update": "2017-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03190278", "title": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03203369", "title": "Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN", "status": "TERMINATED", "last_update": "2019-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222674", "title": "Multi-CAR T Cell Therapy for Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03473457", "title": "CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-09-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03556982", "title": "CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia\uff08AML\uff09", "status": "UNKNOWN", "last_update": "2018-06-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631576", "title": "CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)", "status": "UNKNOWN", "last_update": "2020-01-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03672851", "title": "Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia", "status": "TERMINATED", "last_update": "2019-09-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766126", "title": "Lentivirally Redirected CD123 Autologous T Cells in AML", "status": "TERMINATED", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03796390", "title": "Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia", "status": "UNKNOWN", "last_update": "2019-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010877", "title": "Multiple CAR-T Cell Therapy Targeting AML", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04014881", "title": "Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.", "status": "UNKNOWN", "last_update": "2019-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04106076", "title": "Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2020-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04265963", "title": "CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04272125", "title": "Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-04-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04599543", "title": "IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2020-10-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04678336", "title": "CD123 Redirected T Cells for AML in Pediatric Subjects", "status": "TERMINATED", "last_update": "2025-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513612", "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies", "status": "WITHDRAWN", "last_update": "2023-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05574608", "title": "Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-04-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05995041", "title": "Universal CAR-T Cells Targeting AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07201727", "title": "CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD123", "IL3RA", "IL-3 receptor alpha", "tagraxofusp", "Elzonris", "flotetuzumab", "pivekimab", "IMGN632", "MB-102" ] }, "CLL-1": { "n": 38, "n_observational": 1, "n_active": 18, "n_withdrawn": 3, "trials": [ { "nct": "NCT06017258", "title": "A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06118788", "title": "Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06307054", "title": "CLL-1 CAR-NK Cells for Relapsed/Refractory AML", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680752", "title": "Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS", "status": "RECRUITING", "last_update": "2025-12-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06880354", "title": "A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07036250", "title": "Clinical Study of U32 in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198867", "title": "A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07668557", "title": "Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03038230", "title": "MCLA-117 in Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2025-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222674", "title": "Multi-CAR T Cell Therapy for Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631576", "title": "CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)", "status": "UNKNOWN", "last_update": "2020-01-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03795779", "title": "CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies", "status": "UNKNOWN", "last_update": "2021-05-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010877", "title": "Multiple CAR-T Cell Therapy Targeting AML", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04219163", "title": "Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789408", "title": "Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2025-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04884984", "title": "Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2021-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923919", "title": "Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-07-13", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016063", "title": "Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215015", "title": "Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-01-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05248685", "title": "Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2025-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467202", "title": "Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467254", "title": "Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05654779", "title": "CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943314", "title": "Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2023-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05987696", "title": "Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05995041", "title": "Universal CAR-T Cells Targeting AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06027853", "title": "Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-09-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06110208", "title": "Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML", "status": "TERMINATED", "last_update": "2025-02-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06128044", "title": "CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2025-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06347458", "title": "BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06367673", "title": "Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2024-04-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07201727", "title": "CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07336875", "title": "Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-13", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07338357", "title": "Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML", "status": "WITHDRAWN", "last_update": "2026-08-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07342244", "title": "Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07370064", "title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432100", "title": "Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 29, "n_observational": 0, "n_active": 14, "n_withdrawn": 3, "trials": [ { "nct": "NCT06017258", "title": "A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06307054", "title": "CLL-1 CAR-NK Cells for Relapsed/Refractory AML", "status": "RECRUITING", "last_update": "2025-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680752", "title": "Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS", "status": "RECRUITING", "last_update": "2025-12-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06880354", "title": "A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07668557", "title": "Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03222674", "title": "Multi-CAR T Cell Therapy for Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631576", "title": "CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)", "status": "UNKNOWN", "last_update": "2020-01-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04010877", "title": "Multiple CAR-T Cell Therapy Targeting AML", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04219163", "title": "Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04884984", "title": "Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2021-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923919", "title": "Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-07-13", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016063", "title": "Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05248685", "title": "Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2025-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467202", "title": "Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05467254", "title": "Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML", "status": "UNKNOWN", "last_update": "2022-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05943314", "title": "Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2023-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05987696", "title": "Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05995041", "title": "Universal CAR-T Cells Targeting AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06027853", "title": "Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-09-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06110208", "title": "Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML", "status": "TERMINATED", "last_update": "2025-02-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06128044", "title": "CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2025-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06367673", "title": "Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2024-04-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07201727", "title": "CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07336875", "title": "Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-13", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07338357", "title": "Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML", "status": "WITHDRAWN", "last_update": "2026-08-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07342244", "title": "Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07370064", "title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07432100", "title": "Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CLL-1", "CLL1", "CLEC12A", "C-type lectin-like molecule-1" ] }, "CD70": { "n": 15, "n_observational": 0, "n_active": 12, "n_withdrawn": 0, "trials": [ { "nct": "NCT04662294", "title": "CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases", "status": "RECRUITING", "last_update": "2021-11-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06326463", "title": "CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06696846", "title": "CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03030612", "title": "A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2023-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04023526", "title": "A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150887", "title": "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227847", "title": "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04241549", "title": "A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment", "status": "COMPLETED", "last_update": "2023-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673057", "title": "Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06345027", "title": "Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06384261", "title": "A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492304", "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07336875", "title": "Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-13", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07676006", "title": "A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07696481", "title": "Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 6, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT04662294", "title": "CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases", "status": "RECRUITING", "last_update": "2021-11-04", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06326463", "title": "CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies", "status": "RECRUITING", "last_update": "2026-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06696846", "title": "CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06345027", "title": "Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07336875", "title": "Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-13", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07676006", "title": "A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD70", "cusatuzumab" ] }, "FLT3": { "n": 168, "n_observational": 32, "n_active": 59, "n_withdrawn": 10, "trials": [ { "nct": "NCT02115295", "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140487", "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385290", "title": "Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)", "status": "RECRUITING", "last_update": "2025-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04581512", "title": "Study to Evaluate the Safety and Tolerability of EP0042", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024552", "title": "Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445011", "title": "Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2022-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05586074", "title": "HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703126", "title": "Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML", "status": "RECRUITING", "last_update": "2024-11-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756777", "title": "A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05886049", "title": "A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05947344", "title": "A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2025-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022003", "title": "Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects \u226518 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06221683", "title": "Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06222580", "title": "SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06235801", "title": "A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06262438", "title": "CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients", "status": "RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265545", "title": "Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313437", "title": "Revumenib in Combination With 7+3 + Midostaurin in AML", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06317649", "title": "Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06366789", "title": "Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06696183", "title": "Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760260", "title": "Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-01-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06786533", "title": "Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06824168", "title": "Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972641", "title": "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117422", "title": "Venetoclax-Decitabine in Untreated Elderly/Unfit AML", "status": "RECRUITING", "last_update": "2025-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07131059", "title": "MRD-positive AML Clinical Study", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07137637", "title": "HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259707", "title": "Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07463651", "title": "MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548710", "title": "Study of SA+X in the Treatment of Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07712848", "title": "DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006223", "title": "flt3L in Treating Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006225", "title": "Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer", "status": "COMPLETED", "last_update": "2012-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030186", "title": "Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation", "status": "COMPLETED", "last_update": "2012-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00045942", "title": "PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)", "status": "COMPLETED", "last_update": "2017-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079482", "title": "Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00233454", "title": "Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia", "status": "COMPLETED", "last_update": "2018-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00373373", "title": "Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML", "status": "COMPLETED", "last_update": "2009-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00462761", "title": "A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status", "status": "COMPLETED", "last_update": "2020-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00469859", "title": "Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509093", "title": "Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy", "status": "COMPLETED", "last_update": "2020-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00542971", "title": "Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)", "status": "COMPLETED", "last_update": "2018-08-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553202", "title": "Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2020-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00651261", "title": "Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00779480", "title": "Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)", "status": "TERMINATED", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783653", "title": "Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years", "status": "COMPLETED", "last_update": "2020-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00866281", "title": "A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia", "status": "TERMINATED", "last_update": "2015-12-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00915252", "title": "Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2012-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00943943", "title": "Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations", "status": "COMPLETED", "last_update": "2017-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00989261", "title": "Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01093573", "title": "Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01253070", "title": "Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01349049", "title": "Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2020-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01371981", "title": "Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01390337", "title": "A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01398501", "title": "Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant", "status": "COMPLETED", "last_update": "2017-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01468467", "title": "A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01477606", "title": "Protocol in Acute Myeloid Leukemia With FLT3-ITD", "status": "COMPLETED", "last_update": "2020-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522469", "title": "Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations", "status": "COMPLETED", "last_update": "2024-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01534260", "title": "Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype", "status": "COMPLETED", "last_update": "2018-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565668", "title": "Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01573247", "title": "Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2016-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01657682", "title": "A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations", "status": "COMPLETED", "last_update": "2023-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01830361", "title": "Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML", "status": "COMPLETED", "last_update": "2020-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01831726", "title": "Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib", "status": "COMPLETED", "last_update": "2017-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01883362", "title": "Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML", "status": "COMPLETED", "last_update": "2021-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02039726", "title": "(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02196857", "title": "Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02283177", "title": "A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations", "status": "COMPLETED", "last_update": "2024-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02298166", "title": "Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations", "status": "TERMINATED", "last_update": "2021-10-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02310321", "title": "A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.", "status": "COMPLETED", "last_update": "2025-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02323607", "title": "Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations", "status": "COMPLETED", "last_update": "2019-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02400255", "title": "Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2023-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02400281", "title": "Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2024-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02418000", "title": "A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations", "status": "TERMINATED", "last_update": "2019-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02421939", "title": "A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530476", "title": "Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2020-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02532010", "title": "Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML", "status": "TERMINATED", "last_update": "2018-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02634827", "title": "Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02668653", "title": "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2024-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675478", "title": "Phase 1 Study of Quizartinib", "status": "COMPLETED", "last_update": "2019-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02723435", "title": "Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant", "status": "WITHDRAWN", "last_update": "2018-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02728050", "title": "Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2023-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02752035", "title": "A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy", "status": "COMPLETED", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756962", "title": "Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02789254", "title": "FLYSYN in MRD Positive AML", "status": "COMPLETED", "last_update": "2023-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02829840", "title": "Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)", "status": "WITHDRAWN", "last_update": "2017-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927262", "title": "A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02984995", "title": "Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02997202", "title": "A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2025-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03135054", "title": "Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD", "status": "UNKNOWN", "last_update": "2020-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164057", "title": "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170895", "title": "Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD", "status": "COMPLETED", "last_update": "2020-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03182244", "title": "A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03250338", "title": "Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258931", "title": "Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280030", "title": "A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML", "status": "COMPLETED", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03324243", "title": "A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2019-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03379727", "title": "Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.", "status": "COMPLETED", "last_update": "2024-02-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03412292", "title": "MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)", "status": "UNKNOWN", "last_update": "2022-01-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03512197", "title": "A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2023-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552029", "title": "Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2022-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03609060", "title": "Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03622541", "title": "Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD", "status": "COMPLETED", "last_update": "2020-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03642236", "title": "Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML", "status": "UNKNOWN", "last_update": "2018-08-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03690115", "title": "Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients", "status": "COMPLETED", "last_update": "2025-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03730012", "title": "A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2024-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735875", "title": "Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03760445", "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML", "status": "WITHDRAWN", "last_update": "2020-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03793478", "title": "Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836209", "title": "Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03900949", "title": "Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03922100", "title": "Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04015024", "title": "A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients", "status": "UNKNOWN", "last_update": "2019-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04027309", "title": "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04107727", "title": "Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04174612", "title": "AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance", "status": "UNKNOWN", "last_update": "2022-03-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209725", "title": "A Study of CPX-351 (Vyxeos\u2122) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04240002", "title": "A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2026-01-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278768", "title": "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "SUSPENDED", "last_update": "2026-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04326439", "title": "AflacLL1901 (CHOA-AML)", "status": "TERMINATED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04496999", "title": "HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.", "status": "TERMINATED", "last_update": "2022-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04518345", "title": "TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-02-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04669067", "title": "TL-895 and KRT-232 Study in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04676243", "title": "Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML", "status": "WITHDRAWN", "last_update": "2022-05-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04716114", "title": "A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated", "status": "UNKNOWN", "last_update": "2021-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752527", "title": "Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features", "status": "UNKNOWN", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842370", "title": "Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML", "status": "UNKNOWN", "last_update": "2021-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04896112", "title": "A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982354", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2024-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05017883", "title": "TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-11-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05023707", "title": "Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-12-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05028751", "title": "A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061147", "title": "A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)", "status": "UNKNOWN", "last_update": "2021-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177731", "title": "Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05199051", "title": "A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241093", "title": "A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2025-04-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241106", "title": "A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2024-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05279859", "title": "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies", "status": "WITHDRAWN", "last_update": "2022-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05313958", "title": "Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05330377", "title": "GM-CLAG in Relapsed/Refractory FLT3-mutated AML", "status": "WITHDRAWN", "last_update": "2023-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05432401", "title": "TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-06-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520567", "title": "A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05546580", "title": "Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05876832", "title": "A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)", "status": "NOT_YET_RECRUITING", "last_update": "2023-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05918692", "title": "A Phase 1 Study of BMF-500 in Adults With Acute Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073730", "title": "Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285136", "title": "Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult", "status": "UNKNOWN", "last_update": "2024-02-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06325748", "title": "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06578247", "title": "Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06643195", "title": "Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667973", "title": "Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06744556", "title": "HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06763666", "title": "CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07084584", "title": "ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07407140", "title": "VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07425808", "title": "FLT3-ITD Targeted Therapy in Fit AML Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07726576", "title": "Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07755202", "title": "Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 5, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05445011", "title": "Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2022-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760260", "title": "Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-01-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06786533", "title": "Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML", "status": "RECRUITING", "last_update": "2025-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05023707", "title": "Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-12-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06325748", "title": "SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "FLT3", "CD135" ] }, "CD7": { "n": 15, "n_observational": 0, "n_active": 7, "n_withdrawn": 1, "trials": [ { "nct": "NCT07109518", "title": "uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153068", "title": "SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00354172", "title": "Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02742727", "title": "CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033302", "title": "Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762485", "title": "Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04938115", "title": "Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia", "status": "COMPLETED", "last_update": "2024-06-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05377827", "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "status": "SUSPENDED", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513612", "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies", "status": "WITHDRAWN", "last_update": "2023-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768035", "title": "Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide", "status": "UNKNOWN", "last_update": "2023-09-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05907603", "title": "Research Development\uff08RD\uff0913-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7\uff08CD7\uff09+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05995028", "title": "Universal 4SCAR7U Targeting CD7-positive Malignancies", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07201727", "title": "CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07784309", "title": "A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 11, "n_observational": 0, "n_active": 5, "n_withdrawn": 1, "trials": [ { "nct": "NCT07109518", "title": "uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153068", "title": "SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-12-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523555", "title": "Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02742727", "title": "CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04033302", "title": "Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762485", "title": "Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04938115", "title": "Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia", "status": "COMPLETED", "last_update": "2024-06-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05377827", "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies", "status": "SUSPENDED", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513612", "title": "Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies", "status": "WITHDRAWN", "last_update": "2023-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05907603", "title": "Research Development\uff08RD\uff0913-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7\uff08CD7\uff09+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07201727", "title": "CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD7" ] }, "WT1": { "n": 75, "n_observational": 8, "n_active": 5, "n_withdrawn": 2, "trials": [ { "nct": "NCT02203903", "title": "Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07645469", "title": "FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002673", "title": "Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2010-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003107", "title": "Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors", "status": "COMPLETED", "last_update": "2014-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003408", "title": "Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer", "status": "COMPLETED", "last_update": "2013-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003538", "title": "Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation", "status": "COMPLETED", "last_update": "2014-05-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003883", "title": "Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation", "status": "COMPLETED", "last_update": "2010-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003887", "title": "Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2011-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003938", "title": "Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients", "status": "COMPLETED", "last_update": "2012-09-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004230", "title": "Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2012-06-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00008359", "title": "Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment", "status": "COMPLETED", "last_update": "2013-01-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00010283", "title": "Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon", "status": "COMPLETED", "last_update": "2010-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00014391", "title": "Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2010-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00020527", "title": "Caspofungin Acetate in Treating Children With Fever and Neutropenia", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00030108", "title": "Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy", "status": "COMPLETED", "last_update": "2012-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00036712", "title": "Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation", "status": "UNKNOWN", "last_update": "2013-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00045292", "title": "Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2010-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00052520", "title": "Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2017-03-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00066599", "title": "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079222", "title": "Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00080873", "title": "Traumeel\u00ae S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2016-01-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00118326", "title": "Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease", "status": "COMPLETED", "last_update": "2010-05-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00153582", "title": "WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2006-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00179829", "title": "WT1 for the Detection of Minimal Residual Disease", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00270452", "title": "Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00349024", "title": "Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer", "status": "UNKNOWN", "last_update": "2013-09-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357084", "title": "Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant", "status": "COMPLETED", "last_update": "2010-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00378781", "title": "Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection", "status": "WITHDRAWN", "last_update": "2012-02-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00398138", "title": "Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma", "status": "COMPLETED", "last_update": "2016-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00433745", "title": "Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy", "status": "COMPLETED", "last_update": "2014-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00488592", "title": "Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers", "status": "COMPLETED", "last_update": "2021-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509691", "title": "Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy", "status": "COMPLETED", "last_update": "2017-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00569283", "title": "Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant", "status": "COMPLETED", "last_update": "2013-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "status": "TERMINATED", "last_update": "2017-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00624962", "title": "Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors", "status": "WITHDRAWN", "last_update": "2014-12-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00665002", "title": "Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2015-02-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00672152", "title": "A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation", "status": "TERMINATED", "last_update": "2013-12-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00725283", "title": "Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2018-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00769613", "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections", "status": "UNKNOWN", "last_update": "2013-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00834002", "title": "Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission", "status": "COMPLETED", "last_update": "2010-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923910", "title": "Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood", "status": "COMPLETED", "last_update": "2017-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00965224", "title": "Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01051063", "title": "Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy", "status": "COMPLETED", "last_update": "2018-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01132547", "title": "Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer", "status": "TERMINATED", "last_update": "2015-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01154816", "title": "Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia", "status": "COMPLETED", "last_update": "2020-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01266083", "title": "WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)", "status": "COMPLETED", "last_update": "2024-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01334060", "title": "WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation", "status": "COMPLETED", "last_update": "2018-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01440920", "title": "A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2021-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01475370", "title": "Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)", "status": "COMPLETED", "last_update": "2021-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01513109", "title": "Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2012-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01621542", "title": "Clinical Study of WT2725 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2019-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01621724", "title": "WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01640301", "title": "Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant", "status": "TERMINATED", "last_update": "2022-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01686334", "title": "Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01734304", "title": "DC Vaccination for Postremission Therapy in AML", "status": "COMPLETED", "last_update": "2018-10-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01809392", "title": "Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01819558", "title": "Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy", "status": "COMPLETED", "last_update": "2015-03-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01842139", "title": "Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission", "status": "COMPLETED", "last_update": "2018-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02405338", "title": "DC Vaccination for Post-remission Therapy in AML", "status": "COMPLETED", "last_update": "2020-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02498665", "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2023-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02550535", "title": "A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02750995", "title": "Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML", "status": "COMPLETED", "last_update": "2020-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02770820", "title": "Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02895412", "title": "Infection and Tumour Antigen Cellular Therapy", "status": "UNKNOWN", "last_update": "2016-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03083054", "title": "Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2020-10-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03291444", "title": "CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS", "status": "UNKNOWN", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03761914", "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers", "status": "COMPLETED", "last_update": "2024-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04079296", "title": "A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229979", "title": "Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04284228", "title": "Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT", "status": "UNKNOWN", "last_update": "2024-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04679194", "title": "Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT", "status": "TERMINATED", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04747002", "title": "Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine \"Dainippon Sumitomo Phama(DSP)-7888\" for Acute Myeloid Leukemia Patients.", "status": "UNKNOWN", "last_update": "2021-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05000801", "title": "Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-08-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05066165", "title": "Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 15, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT02203903", "title": "Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07645469", "title": "FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003887", "title": "Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2011-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00769613", "title": "Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections", "status": "UNKNOWN", "last_update": "2013-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00965224", "title": "Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01513109", "title": "Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2012-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01621724", "title": "WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01640301", "title": "Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant", "status": "TERMINATED", "last_update": "2022-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02550535", "title": "A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02770820", "title": "Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-10-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02895412", "title": "Infection and Tumour Antigen Cellular Therapy", "status": "UNKNOWN", "last_update": "2016-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03083054", "title": "Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2020-10-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03291444", "title": "CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS", "status": "UNKNOWN", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04284228", "title": "Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT", "status": "UNKNOWN", "last_update": "2024-01-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04679194", "title": "Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT", "status": "TERMINATED", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "WT1", "Wilms tumor 1", "galinpepimut" ] }, "NKG2D": { "n": 11, "n_observational": 0, "n_active": 5, "n_withdrawn": 1, "trials": [ { "nct": "NCT07617285", "title": "Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02203825", "title": "Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands", "status": "COMPLETED", "last_update": "2018-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03018405", "title": "A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications", "status": "UNKNOWN", "last_update": "2019-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03466320", "title": "DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2", "status": "COMPLETED", "last_update": "2021-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03612739", "title": "EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2", "status": "WITHDRAWN", "last_update": "2019-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623944", "title": "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04658004", "title": "NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2020-12-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05247957", "title": "NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-01-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05319249", "title": "Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2024-04-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05734898", "title": "NKG2D CAR-NK & r/rAML", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07370064", "title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 6, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT07617285", "title": "Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02203825", "title": "Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands", "status": "COMPLETED", "last_update": "2018-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623944", "title": "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04658004", "title": "NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2020-12-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05247957", "title": "NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-01-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07370064", "title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "NKG2D", "NKG2D ligand", "NKG2DL", "CYAD-01" ] } }, "by_drug": { "4SC-203": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01054937", "title": "Single Dose Study With 4SC-203 in Healthy Volunteers", "status": "COMPLETED", "last_update": "2011-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AKN-028": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01573247", "title": "Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2016-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AMG553": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT03904069", "title": "Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML", "status": "WITHDRAWN", "last_update": "2023-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "APG-2575": { "n": 5, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT04501120", "title": "Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06389292", "title": "A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964518", "title": "A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)", "status": "UNKNOWN", "last_update": "2023-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07597941", "title": "Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07813390", "title": "Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AT-9283": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00522990", "title": "Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias", "status": "TERMINATED", "last_update": "2024-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01431664", "title": "AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2014-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AVAPRITINIB": { "n": 9, "n_observational": 1, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT06221683", "title": "Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06316960", "title": "Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06783790", "title": "Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT", "status": "RECRUITING", "last_update": "2025-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07028073", "title": "A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-06-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07131059", "title": "MRD-positive AML Clinical Study", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02561988", "title": "(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies", "status": "COMPLETED", "last_update": "2023-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580655", "title": "(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis", "status": "COMPLETED", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05821738", "title": "Avapritinib in CBF-AML With KIT Mutations", "status": "UNKNOWN", "last_update": "2023-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06765915", "title": "Avapritinib Maintenance for AML With KIT Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AVE-9633": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00543972", "title": "Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2009-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AZACITIDINE": { "n": 194, "n_observational": 6, "n_active": 69, "n_withdrawn": 13, "trials": [ { "nct": "NCT00801489", "title": "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03471260", "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04275518", "title": "A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.", "status": "RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04771130", "title": "A Study of BGB-11417 in Participants With Myeloid Malignancies", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05287568", "title": "CC-486 and Venetoclax for Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431257", "title": "Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05566054", "title": "Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia", "status": "RECRUITING", "last_update": "2025-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05584761", "title": "Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML", "status": "RECRUITING", "last_update": "2022-10-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05586074", "title": "HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05736965", "title": "A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Na\u00efve Participants With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2023-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05772273", "title": "PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05788679", "title": "A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS", "status": "RECRUITING", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06014489", "title": "A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177067", "title": "Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06220162", "title": "VAC Regimen for AML Patients Who Failed to Response to VA Regimen", "status": "RECRUITING", "last_update": "2026-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256627", "title": "The Maintenance Treatment of \"ITIVA\" in AML Patients", "status": "RECRUITING", "last_update": "2024-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265545", "title": "Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06301425", "title": "MRD Response-adapted Allo-HSCT for Adverse-risk AML", "status": "RECRUITING", "last_update": "2024-07-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06316960", "title": "Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06379360", "title": "Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients", "status": "RECRUITING", "last_update": "2026-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498973", "title": "Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06504459", "title": "Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06571825", "title": "RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR", "status": "RECRUITING", "last_update": "2024-08-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06737523", "title": "Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML", "status": "RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06741722", "title": "Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06783790", "title": "Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT", "status": "RECRUITING", "last_update": "2025-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810791", "title": "HVA vs IA/DA or VA in the Treatment of ND HR-AML", "status": "RECRUITING", "last_update": "2025-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06886425", "title": "Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies", "status": "RECRUITING", "last_update": "2025-03-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06928376", "title": "A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007312", "title": "Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07075016", "title": "Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07078591", "title": "Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2025-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392242", "title": "A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07514936", "title": "Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548710", "title": "Study of SA+X in the Treatment of Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002831", "title": "Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia", "status": "COMPLETED", "last_update": "2018-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079378", "title": "Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101179", "title": "MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-10-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114257", "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00275080", "title": "Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2014-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313586", "title": "Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2017-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324220", "title": "A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2015-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00350818", "title": "Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)", "status": "COMPLETED", "last_update": "2012-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00416598", "title": "Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00454480", "title": "Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-08-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00569010", "title": "Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00624936", "title": "Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2017-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00666497", "title": "Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2015-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691938", "title": "LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00760084", "title": "Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2011-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00861874", "title": "A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00866073", "title": "Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2009-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00887068", "title": "Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00911066", "title": "MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2013-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923234", "title": "Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes", "status": "TERMINATED", "last_update": "2013-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968071", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01067274", "title": "ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)", "status": "WITHDRAWN", "last_update": "2015-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130662", "title": "Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01149408", "title": "Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2015-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01168219", "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01202877", "title": "PKC412 and 5-Azacytidine", "status": "COMPLETED", "last_update": "2018-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01254890", "title": "Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2016-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01352650", "title": "Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01358734", "title": "A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects \u2265 65 Years With Newly-Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01369368", "title": "Treatment of Acute Leukemia Relapse After Allotransplantation", "status": "UNKNOWN", "last_update": "2015-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01462578", "title": "Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)", "status": "COMPLETED", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01519011", "title": "Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine", "status": "COMPLETED", "last_update": "2019-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522976", "title": "Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01541280", "title": "VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2016-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01613976", "title": "A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01627041", "title": "Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01633099", "title": "Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients", "status": "UNKNOWN", "last_update": "2012-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01687400", "title": "Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01690507", "title": "Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML\uff09", "status": "COMPLETED", "last_update": "2016-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01798901", "title": "AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2018-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01835587", "title": "Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).", "status": "COMPLETED", "last_update": "2018-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01839240", "title": "Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2020-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01869114", "title": "Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01893320", "title": "Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2022-02-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073838", "title": "Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML", "status": "COMPLETED", "last_update": "2023-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02084563", "title": "Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2016-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02109744", "title": "Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients", "status": "COMPLETED", "last_update": "2022-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02121418", "title": "Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm", "status": "COMPLETED", "last_update": "2018-04-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02124174", "title": "Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS", "status": "UNKNOWN", "last_update": "2021-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02196857", "title": "Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02204020", "title": "Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS", "status": "WITHDRAWN", "last_update": "2018-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02303782", "title": "A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)", "status": "WITHDRAWN", "last_update": "2016-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02319135", "title": "Azacytidine (Vidaza\u00ae) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2020-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02397720", "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02399917", "title": "Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2019-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02441803", "title": "Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2024-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02458235", "title": "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2020-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02472145", "title": "An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2019-03-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02577406", "title": "An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation", "status": "COMPLETED", "last_update": "2025-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02677922", "title": "A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02719574", "title": "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation", "status": "COMPLETED", "last_update": "2026-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02752035", "title": "A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy", "status": "COMPLETED", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02829840", "title": "Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)", "status": "WITHDRAWN", "last_update": "2017-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02890329", "title": "Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02995655", "title": "CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02996474", "title": "Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03063944", "title": "STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2025-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03092674", "title": "Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03146871", "title": "Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent", "status": "TERMINATED", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03217838", "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.", "status": "TERMINATED", "last_update": "2022-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236857", "title": "A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies", "status": "COMPLETED", "last_update": "2023-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03298516", "title": "A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy", "status": "COMPLETED", "last_update": "2019-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356080", "title": "DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess", "status": "UNKNOWN", "last_update": "2017-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03358719", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03395873", "title": "Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy", "status": "TERMINATED", "last_update": "2019-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03397173", "title": "TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid", "status": "COMPLETED", "last_update": "2021-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03493646", "title": "Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486", "status": "COMPLETED", "last_update": "2024-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03530683", "title": "A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma", "status": "TERMINATED", "last_update": "2024-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03745352", "title": "Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2023-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03752138", "title": "TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2019-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813147", "title": "Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813186", "title": "Effect of Food on Blood Levels of ASTX727", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03814005", "title": "A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems", "status": "COMPLETED", "last_update": "2024-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03855371", "title": "Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS", "status": "UNKNOWN", "last_update": "2022-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03926624", "title": "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03978364", "title": "A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC", "status": "UNKNOWN", "last_update": "2019-06-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04051996", "title": "GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086264", "title": "IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04102020", "title": "A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04139434", "title": "Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML", "status": "COMPLETED", "last_update": "2026-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150029", "title": "A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy", "status": "TERMINATED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150887", "title": "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188405", "title": "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227847", "title": "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04248595", "title": "Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML", "status": "UNKNOWN", "last_update": "2022-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04277442", "title": "Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04336982", "title": "A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358393", "title": "A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS", "status": "UNKNOWN", "last_update": "2024-02-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04372433", "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine \u00b1 Venetoclax in Patients in AML and CMML", "status": "COMPLETED", "last_update": "2025-02-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04424147", "title": "Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML", "status": "COMPLETED", "last_update": "2022-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04476199", "title": "Venetoclax and Decitabine Assessment in Patients (\u226560 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04518345", "title": "TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-02-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04712942", "title": "Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat", "status": "COMPLETED", "last_update": "2023-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04722952", "title": "PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine\uff0cCytarabine, G-CSF for Refractory or Relapsed AML", "status": "UNKNOWN", "last_update": "2021-12-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752527", "title": "Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features", "status": "UNKNOWN", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809181", "title": "Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891757", "title": "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04904237", "title": "Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.", "status": "UNKNOWN", "last_update": "2021-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905407", "title": "Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2025-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964505", "title": "Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973618", "title": "Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML", "status": "WITHDRAWN", "last_update": "2021-12-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04980885", "title": "A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05029141", "title": "New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05042531", "title": "Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-04-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05053425", "title": "Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144243", "title": "Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05246384", "title": "Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2022-10-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05262465", "title": "Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML", "status": "UNKNOWN", "last_update": "2022-03-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361057", "title": "Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients", "status": "TERMINATED", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426798", "title": "Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes", "status": "UNKNOWN", "last_update": "2022-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433532", "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05471700", "title": "Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2025-09-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05641259", "title": "A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML", "status": "UNKNOWN", "last_update": "2024-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05720988", "title": "Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05744440", "title": "Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-02-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823480", "title": "Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823714", "title": "Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05833438", "title": "Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05883956", "title": "A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073730", "title": "Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06105658", "title": "Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML", "status": "UNKNOWN", "last_update": "2023-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06158100", "title": "Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)", "status": "TERMINATED", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06252584", "title": "Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445907", "title": "Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06514261", "title": "Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML", "status": "SUSPENDED", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06754540", "title": "Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06770257", "title": "Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy", "status": "WITHDRAWN", "last_update": "2025-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06903702", "title": "A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07091006", "title": "Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07094464", "title": "Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392814", "title": "Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07407660", "title": "Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486479", "title": "Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07635485", "title": "VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07664839", "title": "Study on the Efficacy and Safety of VA Regimen Compared to \"3+7\" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07686965", "title": "Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748455", "title": "HMA-Venetoclax Induction in Newly Diagnosed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BAY1436032": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03127735", "title": "BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CDX-301": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02200380", "title": "A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs", "status": "TERMINATED", "last_update": "2017-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CEDIRANIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00321581", "title": "AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00475150", "title": "Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CENERSEN": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00074737", "title": "Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML", "status": "COMPLETED", "last_update": "2014-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00967512", "title": "Aezea\u00ae (Cenersen) and Chemotherapy for AML Subjects \u2265 55 Years of Age With No Response to Frontline Induction Course", "status": "WITHDRAWN", "last_update": "2014-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CERITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "CRENOLANIB": { "n": 13, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT01522469", "title": "Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations", "status": "COMPLETED", "last_update": "2024-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01657682", "title": "A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations", "status": "COMPLETED", "last_update": "2023-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02270788", "title": "Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies", "status": "COMPLETED", "last_update": "2017-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02283177", "title": "A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations", "status": "COMPLETED", "last_update": "2024-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02298166", "title": "Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations", "status": "TERMINATED", "last_update": "2021-10-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02400255", "title": "Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2023-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02400281", "title": "Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2024-07-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02626338", "title": "Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML", "status": "COMPLETED", "last_update": "2023-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02829840", "title": "Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)", "status": "WITHDRAWN", "last_update": "2017-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03250338", "title": "Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258931", "title": "Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03324243", "title": "A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2019-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CRIZOTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "CSL-360": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00401739", "title": "Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2009-09-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DASATINIB": { "n": 44, "n_observational": 0, "n_active": 3, "n_withdrawn": 5, "trials": [ { "nct": "NCT03595917", "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML", "status": "RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055621", "title": "Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00036738", "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib", "status": "COMPLETED", "last_update": "2020-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101595", "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2011-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103701", "title": "BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2011-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00123487", "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML", "status": "COMPLETED", "last_update": "2014-11-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00255346", "title": "Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)", "status": "COMPLETED", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00298987", "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate", "status": "COMPLETED", "last_update": "2010-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00316953", "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate", "status": "COMPLETED", "last_update": "2013-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00337454", "title": "Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan", "status": "COMPLETED", "last_update": "2011-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00345826", "title": "Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2013-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00349518", "title": "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL", "status": "WITHDRAWN", "last_update": "2016-02-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00390793", "title": "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.", "status": "COMPLETED", "last_update": "2025-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00500006", "title": "A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)", "status": "TERMINATED", "last_update": "2015-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00529763", "title": "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects", "status": "COMPLETED", "last_update": "2023-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00816283", "title": "Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2012-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00850382", "title": "Dasatinib (Sprycel\u2122) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-03-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00860535", "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)", "status": "TERMINATED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00892190", "title": "Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2016-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00978731", "title": "Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study", "status": "COMPLETED", "last_update": "2011-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00982488", "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2016-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01030718", "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL", "status": "COMPLETED", "last_update": "2010-12-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077544", "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)", "status": "COMPLETED", "last_update": "2020-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01207440", "title": "Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238211", "title": "Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01606579", "title": "Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01620216", "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01643603", "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies", "status": "TERMINATED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01667133", "title": "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)", "status": "COMPLETED", "last_update": "2022-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01876953", "title": "Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2022-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013648", "title": "Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel\u2122)", "status": "COMPLETED", "last_update": "2024-02-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02081378", "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL", "status": "COMPLETED", "last_update": "2024-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02113319", "title": "Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2014-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02680951", "title": "Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2018-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779283", "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2020-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02923986", "title": "Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS", "status": "WITHDRAWN", "last_update": "2020-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03173612", "title": "The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03414450", "title": "Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies", "status": "WITHDRAWN", "last_update": "2018-10-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03560908", "title": "Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation", "status": "WITHDRAWN", "last_update": "2025-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04580121", "title": "A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.", "status": "COMPLETED", "last_update": "2024-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05042531", "title": "Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2022-04-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07493408", "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DECITABINE": { "n": 194, "n_observational": 6, "n_active": 69, "n_withdrawn": 10, "trials": [ { "nct": "NCT00801489", "title": "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01515527", "title": "Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02781883", "title": "Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML", "status": "RECRUITING", "last_update": "2025-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04774393", "title": "Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905810", "title": "Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure", "status": "RECRUITING", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04953897", "title": "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04953910", "title": "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010772", "title": "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05184842", "title": "Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190471", "title": "A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05360160", "title": "A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05586074", "title": "HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05636514", "title": "Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06129734", "title": "Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06191978", "title": "A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06316960", "title": "Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06379360", "title": "Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients", "status": "RECRUITING", "last_update": "2026-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06401603", "title": "A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06484062", "title": "Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06511882", "title": "Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536959", "title": "VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS", "status": "RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06651866", "title": "Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients", "status": "RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06672146", "title": "Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06741722", "title": "Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06827899", "title": "Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML", "status": "RECRUITING", "last_update": "2025-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06928662", "title": "Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07101588", "title": "Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117422", "title": "Venetoclax-Decitabine in Untreated Elderly/Unfit AML", "status": "RECRUITING", "last_update": "2025-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07177079", "title": "High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07374029", "title": "Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07437950", "title": "Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07712848", "title": "DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002831", "title": "Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia", "status": "COMPLETED", "last_update": "2018-10-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00042796", "title": "Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "TERMINATED", "last_update": "2013-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079378", "title": "Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00114257", "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00260832", "title": "Trial of Decitabine in Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00275080", "title": "Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2014-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00358644", "title": "Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2013-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00398983", "title": "Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2013-03-04", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00414310", "title": "Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00416598", "title": "Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492401", "title": "Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00671697", "title": "Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00691938", "title": "LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00703300", "title": "Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2014-11-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00760084", "title": "Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2011-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00778375", "title": "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2016-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00861874", "title": "A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00866073", "title": "Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2009-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00867672", "title": "Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00943553", "title": "A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects", "status": "WITHDRAWN", "last_update": "2015-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968071", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00986804", "title": "Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant", "status": "COMPLETED", "last_update": "2016-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130506", "title": "Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130662", "title": "Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01133886", "title": "Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure", "status": "UNKNOWN", "last_update": "2010-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01149408", "title": "Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2015-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01211457", "title": "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2019-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01303796", "title": "A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-06-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01352650", "title": "Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2018-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01378416", "title": "Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2011-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01420926", "title": "Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01483274", "title": "Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation", "status": "WITHDRAWN", "last_update": "2017-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01546038", "title": "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2020-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01567059", "title": "Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2017-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01607645", "title": "Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS", "status": "TERMINATED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01627041", "title": "Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01633099", "title": "Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients", "status": "UNKNOWN", "last_update": "2012-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01687400", "title": "Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2018-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01690507", "title": "Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML\uff09", "status": "COMPLETED", "last_update": "2016-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01707004", "title": "Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01798901", "title": "AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2018-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01806116", "title": "Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01809392", "title": "Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "UNKNOWN", "last_update": "2013-03-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01829503", "title": "Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01853228", "title": "A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2019-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861314", "title": "Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01893320", "title": "Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2022-02-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01902329", "title": "A Safety Study of SGN-CD33A in AML Patients", "status": "COMPLETED", "last_update": "2018-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02072811", "title": "Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (\u226460) With Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2014-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02073838", "title": "Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML", "status": "COMPLETED", "last_update": "2023-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02084563", "title": "Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2016-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02109744", "title": "Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients", "status": "COMPLETED", "last_update": "2022-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02121418", "title": "Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm", "status": "COMPLETED", "last_update": "2018-04-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02141477", "title": "Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2018-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02172872", "title": "\"InDACtion\" vs \"3+7\" Induction in AML", "status": "UNKNOWN", "last_update": "2023-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02190695", "title": "Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS", "status": "COMPLETED", "last_update": "2021-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02197676", "title": "A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response", "status": "COMPLETED", "last_update": "2018-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02204085", "title": "A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-04-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02257138", "title": "Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272478", "title": "Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations", "status": "UNKNOWN", "last_update": "2020-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02316964", "title": "Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2020-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02343939", "title": "Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2019-11-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02412475", "title": "Epigenetic Reprogramming in Relapse AML", "status": "TERMINATED", "last_update": "2019-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02441803", "title": "Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2024-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02446145", "title": "A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients", "status": "TERMINATED", "last_update": "2024-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02472145", "title": "An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2019-03-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02649790", "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications", "status": "COMPLETED", "last_update": "2025-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02723435", "title": "Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant", "status": "WITHDRAWN", "last_update": "2018-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02785900", "title": "Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-12-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02802267", "title": "Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy", "status": "UNKNOWN", "last_update": "2017-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02890329", "title": "Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02920008", "title": "Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02937662", "title": "Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954653", "title": "A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2019-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02996474", "title": "Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03063203", "title": "Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2022-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03063944", "title": "STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2025-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03066648", "title": "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS", "status": "COMPLETED", "last_update": "2025-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03068819", "title": "Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant", "status": "COMPLETED", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03080766", "title": "The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype", "status": "UNKNOWN", "last_update": "2021-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03092674", "title": "Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03146871", "title": "Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent", "status": "TERMINATED", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03217838", "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.", "status": "TERMINATED", "last_update": "2022-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236857", "title": "A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies", "status": "COMPLETED", "last_update": "2023-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03256071", "title": "Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2017-08-21", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03257241", "title": "A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients \u2264 60 Years Old", "status": "UNKNOWN", "last_update": "2021-10-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03303339", "title": "Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2023-02-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03306264", "title": "Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML", "status": "COMPLETED", "last_update": "2024-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356080", "title": "DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess", "status": "UNKNOWN", "last_update": "2017-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03358719", "title": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03381781", "title": "Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations", "status": "UNKNOWN", "last_update": "2018-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03395873", "title": "Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy", "status": "TERMINATED", "last_update": "2019-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03417427", "title": "A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML", "status": "UNKNOWN", "last_update": "2020-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03453255", "title": "DCHA as Postremission Therapy for AML With t(8;21)", "status": "UNKNOWN", "last_update": "2018-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03530085", "title": "Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2020-12-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03613532", "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03752138", "title": "TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2019-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03813186", "title": "Effect of Food on Blood Levels of ASTX727", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03844815", "title": "Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03855371", "title": "Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS", "status": "UNKNOWN", "last_update": "2022-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03926624", "title": "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03969446", "title": "Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory", "status": "SUSPENDED", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03985007", "title": "CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04051996", "title": "GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2021-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04083911", "title": "Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60", "status": "UNKNOWN", "last_update": "2019-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086264", "title": "IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04087967", "title": "Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients", "status": "UNKNOWN", "last_update": "2019-09-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04093570", "title": "A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04155580", "title": "A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-08-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04172844", "title": "Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188405", "title": "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04229979", "title": "Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04277442", "title": "Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04476199", "title": "Venetoclax and Decitabine Assessment in Patients (\u226560 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485052", "title": "Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2023-10-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04493099", "title": "Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML", "status": "WITHDRAWN", "last_update": "2020-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04623944", "title": "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655391", "title": "Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation", "status": "WITHDRAWN", "last_update": "2022-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04657081", "title": "Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04746235", "title": "Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752527", "title": "Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features", "status": "UNKNOWN", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04763928", "title": "Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04817241", "title": "Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04822766", "title": "A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891757", "title": "FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975919", "title": "Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04980404", "title": "Inqovi Maintenance Therapy in Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177731", "title": "Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382390", "title": "Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial", "status": "UNKNOWN", "last_update": "2022-05-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05396859", "title": "Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05426798", "title": "Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes", "status": "UNKNOWN", "last_update": "2022-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05449899", "title": "G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2022-07-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05456269", "title": "A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS", "status": "WITHDRAWN", "last_update": "2023-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796570", "title": "A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05829226", "title": "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2026-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05883956", "title": "A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073730", "title": "Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06113289", "title": "A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2025-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06232655", "title": "Cladribine Venetoclax in Monocytic AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285136", "title": "Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult", "status": "UNKNOWN", "last_update": "2024-02-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06351306", "title": "DEC-C and Thioguanine for R/R AML", "status": "WITHDRAWN", "last_update": "2025-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429098", "title": "Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBF\u03b2::MYH11(+) AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153497", "title": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505160", "title": "Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617363", "title": "ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07761702", "title": "Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07773909", "title": "Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2026-08-21", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07814339", "title": "Hydrochloroquinine & Decitabine With Venetoclax in AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DOVITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01831726", "title": "Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib", "status": "COMPLETED", "last_update": "2017-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DS-1001B": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ENASIDENIB": { "n": 31, "n_observational": 1, "n_active": 18, "n_withdrawn": 2, "trials": [ { "nct": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03383575", "title": "Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03683433", "title": "Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04774393", "title": "Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010772", "title": "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05401097", "title": "IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756777", "title": "A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06672146", "title": "Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01915498", "title": "Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation", "status": "COMPLETED", "last_update": "2024-10-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02577406", "title": "An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation", "status": "COMPLETED", "last_update": "2025-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02677922", "title": "A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03515512", "title": "IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation", "status": "COMPLETED", "last_update": "2025-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03720366", "title": "A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients", "status": "COMPLETED", "last_update": "2024-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03728335", "title": "Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation", "status": "SUSPENDED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03744390", "title": "IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03825796", "title": "CPX-351 Plus Enasidenib for Relapsed AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839771", "title": "A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03881735", "title": "Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation", "status": "WITHDRAWN", "last_update": "2021-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04075747", "title": "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04092179", "title": "Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers", "status": "TERMINATED", "last_update": "2024-01-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04203316", "title": "Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04522895", "title": "IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655391", "title": "Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation", "status": "WITHDRAWN", "last_update": "2022-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04822766", "title": "A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05282459", "title": "Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation", "status": "COMPLETED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05441514", "title": "Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03072043", "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms", "status": "COMPLETED", "last_update": "2022-01-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03588078", "title": "Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine", "status": "UNKNOWN", "last_update": "2020-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03931291", "title": "APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FEDRATINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04282187", "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FF-10101": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03194685", "title": "Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FLOTETUZUMAB": { "n": 6, "n_observational": 1, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT02152956", "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-01-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03739606", "title": "Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer", "status": "WITHDRAWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04158739", "title": "Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04582864", "title": "Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)", "status": "TERMINATED", "last_update": "2024-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04681105", "title": "Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies", "status": "COMPLETED", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05506956", "title": "Post-transplant Flotetuzumab for AML", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FLYSYN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02789254", "title": "FLYSYN in MRD Positive AML", "status": "COMPLETED", "last_update": "2023-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GEMTUZUMAB": { "n": 106, "n_observational": 10, "n_active": 23, "n_withdrawn": 2, "trials": [ { "nct": "NCT00801489", "title": "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01409161", "title": "Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589729", "title": "Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737955", "title": "Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04050280", "title": "CLAG-GO for Patients With Persistent, Relapsed or Refractory AML", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04168502", "title": "Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML", "status": "RECRUITING", "last_update": "2024-11-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385290", "title": "Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)", "status": "RECRUITING", "last_update": "2025-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04793919", "title": "Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia", "status": "RECRUITING", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183035", "title": "Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05558124", "title": "CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904106", "title": "Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994690", "title": "CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients", "status": "RECRUITING", "last_update": "2025-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448013", "title": "A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06917911", "title": "Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003131", "title": "CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse", "status": "COMPLETED", "last_update": "2012-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003407", "title": "Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML", "status": "WITHDRAWN", "last_update": "2023-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003673", "title": "CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse", "status": "COMPLETED", "last_update": "2012-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005962", "title": "Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006122", "title": "Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006265", "title": "Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00008151", "title": "Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2010-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017589", "title": "Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028899", "title": "Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2014-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00037583", "title": "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2009-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00037596", "title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038805", "title": "Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2018-10-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038831", "title": "Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00044733", "title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant", "status": "COMPLETED", "last_update": "2006-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049179", "title": "S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2015-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049517", "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00052299", "title": "Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00070174", "title": "Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy", "status": "COMPLETED", "last_update": "2014-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00077116", "title": "Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085709", "title": "S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089050", "title": "Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2011-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00091234", "title": "Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2012-07-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00121303", "title": "Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2016-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00136084", "title": "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia", "status": "COMPLETED", "last_update": "2012-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143975", "title": "Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)", "status": "COMPLETED", "last_update": "2010-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00195000", "title": "Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00233909", "title": "A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2008-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274781", "title": "Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2015-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00304447", "title": "Study Evaluating the Effect of Corticosteroids on Mylotarg\u00ae Infusion-Related Adverse Events in Patients With Leukemia", "status": "COMPLETED", "last_update": "2009-07-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372593", "title": "Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2021-03-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00413166", "title": "All-trans Retinoic Acid, and Arsenic +/- Idarubicin", "status": "COMPLETED", "last_update": "2019-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00454480", "title": "Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-08-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00460447", "title": "Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation", "status": "UNKNOWN", "last_update": "2007-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00476541", "title": "NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492856", "title": "S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551460", "title": "S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577694", "title": "Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2015-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00658814", "title": "Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00660036", "title": "Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2016-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00669890", "title": "Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML", "status": "TERMINATED", "last_update": "2015-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00673153", "title": "Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2017-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00766116", "title": "Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00798213", "title": "SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)", "status": "TERMINATED", "last_update": "2015-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00860639", "title": "Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk", "status": "COMPLETED", "last_update": "2017-01-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00893399", "title": "Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation", "status": "COMPLETED", "last_update": "2023-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00895934", "title": "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML", "status": "COMPLETED", "last_update": "2019-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00909168", "title": "Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2014-05-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00927498", "title": "A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old", "status": "COMPLETED", "last_update": "2013-07-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00962767", "title": "Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission", "status": "COMPLETED", "last_update": "2009-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968071", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01019317", "title": "Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2016-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01020539", "title": "Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia", "status": "COMPLETED", "last_update": "2021-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01039363", "title": "Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2009-12-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01041040", "title": "LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2013-07-31", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01548911", "title": "Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2018-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01698879", "title": "Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment", "status": "COMPLETED", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723657", "title": "Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2012-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117297", "title": "SCT Plus Immune Therapy in Average Risk AML/MDS", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02182596", "title": "DNR and AraC Combined to Fractionated Mylotarg\u00ae in Patients With First Relapse of AML", "status": "COMPLETED", "last_update": "2014-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02221310", "title": "Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272478", "title": "Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations", "status": "UNKNOWN", "last_update": "2020-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02473146", "title": "Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4", "status": "COMPLETED", "last_update": "2024-02-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02724163", "title": "International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03374332", "title": "Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03390296", "title": "OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03531918", "title": "Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm", "status": "COMPLETED", "last_update": "2023-08-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568994", "title": "Atovaquone (Mepron\u00ae) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03672539", "title": "Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727750", "title": "Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML", "status": "COMPLETED", "last_update": "2022-03-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839446", "title": "Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy", "status": "COMPLETED", "last_update": "2025-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03848754", "title": "Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878927", "title": "CPX-351+GO in Subjects 55 Years Old, or Older, With AML", "status": "TERMINATED", "last_update": "2023-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03900949", "title": "Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03904251", "title": "CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04070768", "title": "Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04093505", "title": "Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)", "status": "TERMINATED", "last_update": "2022-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173585", "title": "TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib", "status": "COMPLETED", "last_update": "2023-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04207190", "title": "Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04326439", "title": "AflacLL1901 (CHOA-AML)", "status": "TERMINATED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04849910", "title": "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS", "status": "TERMINATED", "last_update": "2025-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04915612", "title": "Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05199051", "title": "A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05599360", "title": "Vyxeos for Induction of Low- or Intermediate-risk.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05662904", "title": "Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05716009", "title": "Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML", "status": "TERMINATED", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955261", "title": "A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GEMTUZUMAB OZOGAMICIN": { "n": 104, "n_observational": 9, "n_active": 23, "n_withdrawn": 1, "trials": [ { "nct": "NCT00801489", "title": "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01409161", "title": "Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589729", "title": "Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737955", "title": "Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04050280", "title": "CLAG-GO for Patients With Persistent, Relapsed or Refractory AML", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04168502", "title": "Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML", "status": "RECRUITING", "last_update": "2024-11-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385290", "title": "Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)", "status": "RECRUITING", "last_update": "2025-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04793919", "title": "Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia", "status": "RECRUITING", "last_update": "2024-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183035", "title": "Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05558124", "title": "CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904106", "title": "Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994690", "title": "CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients", "status": "RECRUITING", "last_update": "2025-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06448013", "title": "A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06917911", "title": "Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003131", "title": "CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse", "status": "COMPLETED", "last_update": "2012-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003673", "title": "CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse", "status": "COMPLETED", "last_update": "2012-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005962", "title": "Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006122", "title": "Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006265", "title": "Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00008151", "title": "Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2010-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017589", "title": "Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028899", "title": "Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2014-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00037583", "title": "Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2009-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00037596", "title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038805", "title": "Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2018-10-31", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00038831", "title": "Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00044733", "title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant", "status": "COMPLETED", "last_update": "2006-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049179", "title": "S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2015-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049517", "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00052299", "title": "Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2012-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00070174", "title": "Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy", "status": "COMPLETED", "last_update": "2014-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00077116", "title": "Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2012-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085709", "title": "S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00089050", "title": "Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2011-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00091234", "title": "Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2012-07-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00121303", "title": "Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2016-09-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00136084", "title": "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia", "status": "COMPLETED", "last_update": "2012-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00143975", "title": "Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)", "status": "COMPLETED", "last_update": "2010-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00195000", "title": "Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00233909", "title": "A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2008-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274781", "title": "Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2015-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00304447", "title": "Study Evaluating the Effect of Corticosteroids on Mylotarg\u00ae Infusion-Related Adverse Events in Patients With Leukemia", "status": "COMPLETED", "last_update": "2009-07-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372593", "title": "Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2021-03-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00413166", "title": "All-trans Retinoic Acid, and Arsenic +/- Idarubicin", "status": "COMPLETED", "last_update": "2019-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00454480", "title": "Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2013-08-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00460447", "title": "Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation", "status": "UNKNOWN", "last_update": "2007-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00476541", "title": "NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492856", "title": "S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551460", "title": "S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00577694", "title": "Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2015-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00658814", "title": "Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00660036", "title": "Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2016-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00669890", "title": "Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML", "status": "TERMINATED", "last_update": "2015-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00673153", "title": "Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2017-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00766116", "title": "Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-02-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00798213", "title": "SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)", "status": "TERMINATED", "last_update": "2015-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00860639", "title": "Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk", "status": "COMPLETED", "last_update": "2017-01-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00882102", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)", "status": "COMPLETED", "last_update": "2013-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00893399", "title": "Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation", "status": "COMPLETED", "last_update": "2023-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00895934", "title": "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML", "status": "COMPLETED", "last_update": "2019-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00909168", "title": "Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2014-05-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00927498", "title": "A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old", "status": "COMPLETED", "last_update": "2013-07-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00962767", "title": "Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission", "status": "COMPLETED", "last_update": "2009-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00968071", "title": "Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01019317", "title": "Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2016-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01020539", "title": "Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia", "status": "COMPLETED", "last_update": "2021-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01039363", "title": "Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2009-12-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01041040", "title": "LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2013-07-31", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01548911", "title": "Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2018-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01698879", "title": "Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment", "status": "COMPLETED", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117297", "title": "SCT Plus Immune Therapy in Average Risk AML/MDS", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02182596", "title": "DNR and AraC Combined to Fractionated Mylotarg\u00ae in Patients With First Relapse of AML", "status": "COMPLETED", "last_update": "2014-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02221310", "title": "Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS", "status": "COMPLETED", "last_update": "2023-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272478", "title": "Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations", "status": "UNKNOWN", "last_update": "2020-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02473146", "title": "Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4", "status": "COMPLETED", "last_update": "2024-02-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02724163", "title": "International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03374332", "title": "Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03390296", "title": "OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-09-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03531918", "title": "Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm", "status": "COMPLETED", "last_update": "2023-08-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568994", "title": "Atovaquone (Mepron\u00ae) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03672539", "title": "Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727750", "title": "Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML", "status": "COMPLETED", "last_update": "2022-03-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839446", "title": "Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy", "status": "COMPLETED", "last_update": "2025-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03848754", "title": "Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878927", "title": "CPX-351+GO in Subjects 55 Years Old, or Older, With AML", "status": "TERMINATED", "last_update": "2023-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03900949", "title": "Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03904251", "title": "CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04070768", "title": "Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04093505", "title": "Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)", "status": "TERMINATED", "last_update": "2022-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173585", "title": "TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib", "status": "COMPLETED", "last_update": "2023-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04207190", "title": "Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-11-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04326439", "title": "AflacLL1901 (CHOA-AML)", "status": "TERMINATED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04849910", "title": "Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS", "status": "TERMINATED", "last_update": "2025-07-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04915612", "title": "Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05199051", "title": "A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05599360", "title": "Vyxeos for Induction of Low- or Intermediate-risk.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05662904", "title": "Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05716009", "title": "Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML", "status": "TERMINATED", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955261", "title": "A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GILTERITINIB": { "n": 58, "n_observational": 8, "n_active": 37, "n_withdrawn": 3, "trials": [ { "nct": "NCT02115295", "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04140487", "title": "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04293562", "title": "A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010772", "title": "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024552", "title": "Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML", "status": "RECRUITING", "last_update": "2025-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756777", "title": "A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06001788", "title": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022003", "title": "Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects \u226518 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06221683", "title": "Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06222580", "title": "SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06235801", "title": "A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265545", "title": "Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06317649", "title": "Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06696183", "title": "Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment", "status": "RECRUITING", "last_update": "2025-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117422", "title": "Venetoclax-Decitabine in Untreated Elderly/Unfit AML", "status": "RECRUITING", "last_update": "2025-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07131059", "title": "MRD-positive AML Clinical Study", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259707", "title": "Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML", "status": "RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07463651", "title": "MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548710", "title": "Study of SA+X in the Treatment of Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07712848", "title": "DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02014558", "title": "Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02181660", "title": "Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02236013", "title": "A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-11-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02310321", "title": "A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.", "status": "COMPLETED", "last_update": "2025-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02421939", "title": "A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02561455", "title": "Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial", "status": "COMPLETED", "last_update": "2024-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02752035", "title": "A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy", "status": "COMPLETED", "last_update": "2026-07-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927262", "title": "A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission", "status": "COMPLETED", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02997202", "title": "A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2025-01-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03182244", "title": "A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03625505", "title": "A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2021-09-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03730012", "title": "A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2024-11-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836209", "title": "Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03922100", "title": "Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04027309", "title": "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04240002", "title": "A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2026-01-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04336982", "title": "A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655391", "title": "Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation", "status": "WITHDRAWN", "last_update": "2022-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05028751", "title": "A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05177731", "title": "Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05199051", "title": "A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05279859", "title": "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies", "status": "WITHDRAWN", "last_update": "2022-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05330377", "title": "GM-CLAG in Relapsed/Refractory FLT3-mutated AML", "status": "WITHDRAWN", "last_update": "2023-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520567", "title": "A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05546580", "title": "Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05955261", "title": "A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06652685", "title": "Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667973", "title": "Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06763666", "title": "CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07407140", "title": "VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07425808", "title": "FLT3-ITD Targeted Therapy in Fit AML Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07755202", "title": "Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IDASANUTLIN": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02545283", "title": "A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2022-01-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02670044", "title": "A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy", "status": "COMPLETED", "last_update": "2022-01-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03850535", "title": "A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission", "status": "TERMINATED", "last_update": "2022-06-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04029688", "title": "A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors", "status": "TERMINATED", "last_update": "2024-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IDH305": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT02381886", "title": "A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02826642", "title": "A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2019-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "IMATINIB": { "n": 51, "n_observational": 1, "n_active": 1, "n_withdrawn": 2, "trials": [ { "nct": "NCT00004932", "title": "STI571 in Treating Patients With Recurrent Leukemia", "status": "COMPLETED", "last_update": "2014-02-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00015860", "title": "STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00025415", "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction", "status": "COMPLETED", "last_update": "2013-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00036738", "title": "Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib", "status": "COMPLETED", "last_update": "2020-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00064285", "title": "Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer", "status": "COMPLETED", "last_update": "2010-05-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00081133", "title": "Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2013-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00088231", "title": "PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP", "status": "COMPLETED", "last_update": "2012-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101595", "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2011-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00109707", "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies", "status": "COMPLETED", "last_update": "2021-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00123487", "title": "Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML", "status": "COMPLETED", "last_update": "2014-11-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00154388", "title": "Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases", "status": "COMPLETED", "last_update": "2016-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00167180", "title": "Post Transplant Donor Lymphocyte Infusion", "status": "TERMINATED", "last_update": "2019-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00171223", "title": "An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha", "status": "COMPLETED", "last_update": "2021-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00171249", "title": "An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia", "status": "COMPLETED", "last_update": "2021-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00199186", "title": "Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)", "status": "UNKNOWN", "last_update": "2007-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00219765", "title": "Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients", "status": "TERMINATED", "last_update": "2005-11-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00244829", "title": "Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia", "status": "COMPLETED", "last_update": "2011-11-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00258271", "title": "Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2013-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00268229", "title": "Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00298987", "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate", "status": "COMPLETED", "last_update": "2010-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00316953", "title": "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate", "status": "COMPLETED", "last_update": "2013-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00337454", "title": "Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan", "status": "COMPLETED", "last_update": "2011-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00349518", "title": "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL", "status": "WITHDRAWN", "last_update": "2016-02-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00352677", "title": "Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia", "status": "COMPLETED", "last_update": "2009-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00384228", "title": "A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00386373", "title": "Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00451997", "title": "Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes", "status": "COMPLETED", "last_update": "2012-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00469014", "title": "Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2021-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509093", "title": "Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy", "status": "COMPLETED", "last_update": "2020-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00529763", "title": "Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects", "status": "COMPLETED", "last_update": "2023-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00594555", "title": "A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2008-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00702403", "title": "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML", "status": "COMPLETED", "last_update": "2017-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00707408", "title": "High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)", "status": "COMPLETED", "last_update": "2009-02-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00744081", "title": "Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2023-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00763763", "title": "Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive", "status": "COMPLETED", "last_update": "2011-10-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00852709", "title": "Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias", "status": "TERMINATED", "last_update": "2018-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00860535", "title": "Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)", "status": "TERMINATED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00955916", "title": "CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2014-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00982488", "title": "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2016-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01030718", "title": "Rollover Study of BMS-354825 in Patients With CML and Ph+ALL", "status": "COMPLETED", "last_update": "2010-12-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01066468", "title": "Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec\u00ae Indicated Hematological Disorders.", "status": "TERMINATED", "last_update": "2012-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01077544", "title": "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)", "status": "COMPLETED", "last_update": "2020-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01126814", "title": "A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2015-06-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01279473", "title": "Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01914484", "title": "Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia", "status": "COMPLETED", "last_update": "2020-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02081378", "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL", "status": "COMPLETED", "last_update": "2024-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272777", "title": "A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase", "status": "COMPLETED", "last_update": "2019-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02352558", "title": "A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies", "status": "COMPLETED", "last_update": "2023-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07493408", "title": "Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IMC-EB10": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00887926", "title": "Study of IMC-EB10 in Participant With Leukemia", "status": "TERMINATED", "last_update": "2022-12-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "IVOSIDENIB": { "n": 33, "n_observational": 4, "n_active": 29, "n_withdrawn": 2, "trials": [ { "nct": "NCT02074839", "title": "Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation", "status": "RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03471260", "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04493164", "title": "CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04774393", "title": "Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010772", "title": "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05401097", "title": "IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756777", "title": "A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05907057", "title": "An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265545", "title": "Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06611839", "title": "Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06707493", "title": "Ivosidenib as Post-HSCT Maintenance for AML", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06717958", "title": "Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007949", "title": "a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07075016", "title": "Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07131059", "title": "MRD-positive AML Clinical Study", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392242", "title": "A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507760", "title": "Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548710", "title": "Study of SA+X in the Treatment of Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07607418", "title": "Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02677922", "title": "A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03173248", "title": "Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03503409", "title": "IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03839771", "title": "A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044209", "title": "A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS", "status": "WITHDRAWN", "last_update": "2022-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04176393", "title": "A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation", "status": "COMPLETED", "last_update": "2023-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04250051", "title": "Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2026-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04655391", "title": "Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation", "status": "WITHDRAWN", "last_update": "2022-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07463768", "title": "Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg\u00ae) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "KW-2449": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00346632", "title": "An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2024-05-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00779480", "title": "Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)", "status": "TERMINATED", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LESTAURTINIB": { "n": 3, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00030186", "title": "Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation", "status": "COMPLETED", "last_update": "2012-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00079482", "title": "Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2016-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00469859", "title": "Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LINTUZUMAB": { "n": 14, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT00002609", "title": "Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission", "status": "COMPLETED", "last_update": "2013-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002800", "title": "Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002890", "title": "Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2013-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006045", "title": "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006084", "title": "Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00016159", "title": "Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00283114", "title": "A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2014-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528333", "title": "A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML", "status": "COMPLETED", "last_update": "2015-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02575963", "title": "Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients", "status": "COMPLETED", "last_update": "2023-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03441048", "title": "Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-10-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03705858", "title": "Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2019-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03867682", "title": "Venetoclax and Lintuzumab-Ac225 in AML Patients", "status": "UNKNOWN", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03932318", "title": "Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients", "status": "WITHDRAWN", "last_update": "2023-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06802523", "title": "Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MIDOSTAURIN": { "n": 49, "n_observational": 6, "n_active": 13, "n_withdrawn": 5, "trials": [ { "nct": "NCT02115295", "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385290", "title": "Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)", "status": "RECRUITING", "last_update": "2025-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313437", "title": "Revumenib in Combination With 7+3 + Midostaurin in AML", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00045942", "title": "PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)", "status": "COMPLETED", "last_update": "2017-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00093600", "title": "PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00233454", "title": "Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia", "status": "COMPLETED", "last_update": "2018-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00651261", "title": "Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2021-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00782067", "title": "Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia", "status": "COMPLETED", "last_update": "2018-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00819546", "title": "RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00866281", "title": "A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia", "status": "TERMINATED", "last_update": "2015-12-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01093573", "title": "Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130662", "title": "Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2013-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01161550", "title": "Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML", "status": "COMPLETED", "last_update": "2013-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01174888", "title": "Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01202877", "title": "PKC412 and 5-Azacytidine", "status": "COMPLETED", "last_update": "2018-10-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01477606", "title": "Protocol in Acute Myeloid Leukemia With FLT3-ITD", "status": "COMPLETED", "last_update": "2020-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01830361", "title": "Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML", "status": "COMPLETED", "last_update": "2020-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846624", "title": "Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2018-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01883362", "title": "Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML", "status": "COMPLETED", "last_update": "2021-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02078609", "title": "A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02634827", "title": "Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation", "status": "TERMINATED", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02723435", "title": "Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant", "status": "WITHDRAWN", "last_update": "2018-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02756962", "title": "Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03092674", "title": "Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03207334", "title": "iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)", "status": "WITHDRAWN", "last_update": "2018-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258931", "title": "Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03280030", "title": "A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML", "status": "COMPLETED", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03379727", "title": "Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.", "status": "COMPLETED", "last_update": "2024-02-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03512197", "title": "A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2023-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03591510", "title": "A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03609060", "title": "Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03686345", "title": "Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia", "status": "TERMINATED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03760445", "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML", "status": "WITHDRAWN", "last_update": "2020-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836209", "title": "Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03900949", "title": "Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03951961", "title": "Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation", "status": "TERMINATED", "last_update": "2022-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04027309", "title": "A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04075747", "title": "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04097470", "title": "Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04174612", "title": "AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance", "status": "UNKNOWN", "last_update": "2022-03-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04496999", "title": "HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.", "status": "TERMINATED", "last_update": "2022-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04676243", "title": "Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML", "status": "WITHDRAWN", "last_update": "2022-05-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982354", "title": "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2024-10-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06252584", "title": "Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07425808", "title": "FLT3-ITD Targeted Therapy in Fit AML Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07726576", "title": "Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MOTESANIB": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06247787", "title": "A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320235", "title": "Imetelstat Combinations in Relapsed AML", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583552", "title": "Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVITOCLAX": { "n": 4, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT05222984", "title": "Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05455294", "title": "Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06007911", "title": "Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2024-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NAVTEMADLIN": { "n": 4, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03041688", "title": "Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04113616", "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04190550", "title": "Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04669067", "title": "TL-895 and KRT-232 Study in Acute Myeloid Leukemia", "status": "UNKNOWN", "last_update": "2023-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NINGETINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03125876", "title": "A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2021-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OBATOCLAX": { "n": 3, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00438178", "title": "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies", "status": "COMPLETED", "last_update": "2014-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00684918", "title": "Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2013-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "status": "TERMINATED", "last_update": "2014-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "OBLIMERSEN": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05190471", "title": "A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004862", "title": "Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2013-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017589", "title": "Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2014-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00039117", "title": "Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2015-12-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085124", "title": "Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-06-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "OLUTASIDENIB": { "n": 13, "n_observational": 0, "n_active": 11, "n_withdrawn": 1, "trials": [ { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06543381", "title": "Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06782542", "title": "Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130695", "title": "Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07304011", "title": "Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07471841", "title": "Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486713", "title": "Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604064", "title": "A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02719574", "title": "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation", "status": "COMPLETED", "last_update": "2026-06-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04013880", "title": "ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2020-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153497", "title": "Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07411586", "title": "Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PACRITINIB": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04282187", "title": "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01620216", "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02323607", "title": "Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations", "status": "COMPLETED", "last_update": "2019-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02532010", "title": "Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML", "status": "TERMINATED", "last_update": "2018-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PAZOPANIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01361334", "title": "Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "PEXIDARTINIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02390752", "title": "Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01349049", "title": "Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2020-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PIVEKIMAB SUNIRINE": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT07306832", "title": "A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07581002", "title": "A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06034470", "title": "Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "QUIZARTINIB": { "n": 35, "n_observational": 3, "n_active": 12, "n_withdrawn": 2, "trials": [ { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04047641", "title": "Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06262438", "title": "CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients", "status": "RECRUITING", "last_update": "2025-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769490", "title": "Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06824168", "title": "Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07478991", "title": "Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548710", "title": "Study of SA+X in the Treatment of Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00462761", "title": "A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status", "status": "COMPLETED", "last_update": "2020-05-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00989261", "title": "Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01390337", "title": "A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01411267", "title": "AC220 for Children With Relapsed/Refractory ALL or AML", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01468467", "title": "A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2019-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565668", "title": "Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2019-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01892371", "title": "Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2025-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02039726", "title": "(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02668653", "title": "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2024-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675478", "title": "Phase 1 Study of Quizartinib", "status": "COMPLETED", "last_update": "2019-02-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02829840", "title": "Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)", "status": "WITHDRAWN", "last_update": "2017-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834390", "title": "Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2025-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02984995", "title": "Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03135054", "title": "Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD", "status": "UNKNOWN", "last_update": "2020-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552029", "title": "Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2022-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03723681", "title": "Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2022-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735875", "title": "Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03793478", "title": "Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04107727", "title": "Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)", "status": "COMPLETED", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04112589", "title": "A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment", "status": "UNKNOWN", "last_update": "2022-03-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04128748", "title": "Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209725", "title": "A Study of CPX-351 (Vyxeos\u2122) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04477291", "title": "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS", "status": "TERMINATED", "last_update": "2025-03-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04676243", "title": "Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML", "status": "WITHDRAWN", "last_update": "2022-05-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04687761", "title": "Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old", "status": "COMPLETED", "last_update": "2026-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06578247", "title": "Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07425808", "title": "FLT3-ITD Targeted Therapy in Fit AML Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "REGORAFENIB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03042689", "title": "Study of Regorafenib in Patients With Advanced Myeloid Malignancies", "status": "COMPLETED", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06454409", "title": "Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "REVUMENIB": { "n": 17, "n_observational": 0, "n_active": 15, "n_withdrawn": 1, "trials": [ { "nct": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04065399", "title": "A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05886049", "title": "A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177067", "title": "Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06222580", "title": "SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284486", "title": "A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06313437", "title": "Revumenib in Combination With 7+3 + Midostaurin in AML", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06575296", "title": "Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06652438", "title": "Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07211958", "title": "Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07356154", "title": "A Study of Revumenib and Mezigdomide in People With Leukemia", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05326516", "title": "A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia", "status": "COMPLETED", "last_update": "2024-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05761171", "title": "A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07498465", "title": "A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia", "status": "WITHDRAWN", "last_update": "2026-05-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07563010", "title": "Menin-Inhibitor Targeted Maintenance in AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07605949", "title": "Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07686107", "title": "Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML.\"", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "RIPRETINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02571036", "title": "A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2023-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SEMAXANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00005942", "title": "Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy", "status": "COMPLETED", "last_update": "2013-01-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SIREMADLIN": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT03760445", "title": "HDM201 Added to CT in R/R or Newly Diagnosed AML", "status": "WITHDRAWN", "last_update": "2020-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940352", "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04496999", "title": "HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.", "status": "TERMINATED", "last_update": "2022-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05155709", "title": "A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.", "status": "COMPLETED", "last_update": "2026-05-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05447663", "title": "A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant", "status": "TERMINATED", "last_update": "2025-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SORAFENIB": { "n": 53, "n_observational": 8, "n_active": 15, "n_withdrawn": 1, "trials": [ { "nct": "NCT06221683", "title": "Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532084", "title": "Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen", "status": "RECRUITING", "last_update": "2024-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06972641", "title": "Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation", "status": "RECRUITING", "last_update": "2025-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07117422", "title": "Venetoclax-Decitabine in Untreated Elderly/Unfit AML", "status": "RECRUITING", "last_update": "2025-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07463651", "title": "MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib", "status": "RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07712848", "title": "DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00131989", "title": "Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2013-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00217646", "title": "Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00373373", "title": "Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML", "status": "COMPLETED", "last_update": "2009-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00516828", "title": "Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00542971", "title": "Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)", "status": "COMPLETED", "last_update": "2018-08-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00875745", "title": "Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)", "status": "COMPLETED", "last_update": "2014-09-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00893373", "title": "Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age", "status": "COMPLETED", "last_update": "2016-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00908167", "title": "Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies", "status": "COMPLETED", "last_update": "2018-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00943943", "title": "Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations", "status": "COMPLETED", "last_update": "2017-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01159301", "title": "Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2013-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01253070", "title": "Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2022-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01254890", "title": "Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2016-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01371981", "title": "Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01398501", "title": "Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant", "status": "COMPLETED", "last_update": "2017-03-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01445080", "title": "Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01534260", "title": "Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype", "status": "COMPLETED", "last_update": "2018-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01578109", "title": "Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01620216", "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861314", "title": "Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02135874", "title": "Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia", "status": "COMPLETED", "last_update": "2024-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02196857", "title": "Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation", "status": "COMPLETED", "last_update": "2020-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02270788", "title": "Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies", "status": "COMPLETED", "last_update": "2017-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02412475", "title": "Epigenetic Reprogramming in Relapse AML", "status": "TERMINATED", "last_update": "2019-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02474290", "title": "Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML", "status": "COMPLETED", "last_update": "2019-08-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02530476", "title": "Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2020-03-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02728050", "title": "Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2023-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779283", "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2020-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02829840", "title": "Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)", "status": "WITHDRAWN", "last_update": "2017-06-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03132454", "title": "Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164057", "title": "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170895", "title": "Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD", "status": "COMPLETED", "last_update": "2020-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03247088", "title": "Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03622541", "title": "Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD", "status": "COMPLETED", "last_update": "2020-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03642236", "title": "Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML", "status": "UNKNOWN", "last_update": "2018-08-22", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04326439", "title": "AflacLL1901 (CHOA-AML)", "status": "TERMINATED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752527", "title": "Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features", "status": "UNKNOWN", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04822766", "title": "A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05313958", "title": "Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children", "status": "UNKNOWN", "last_update": "2023-07-27", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05404516", "title": "Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML", "status": "UNKNOWN", "last_update": "2022-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073730", "title": "Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285136", "title": "Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult", "status": "UNKNOWN", "last_update": "2024-02-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06763666", "title": "CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07264010", "title": "Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07425808", "title": "FLT3-ITD Targeted Therapy in Fit AML Patients", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB": { "n": 7, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00387426", "title": "Sunitinib in Treating Patients With Idiopathic Myelofibrosis", "status": "TERMINATED", "last_update": "2014-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783653", "title": "Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years", "status": "COMPLETED", "last_update": "2020-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "status": "COMPLETED", "last_update": "2014-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01620216", "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779283", "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2020-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB MALATE": { "n": 7, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00387426", "title": "Sunitinib in Treating Patients With Idiopathic Myelofibrosis", "status": "TERMINATED", "last_update": "2014-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783653", "title": "Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years", "status": "COMPLETED", "last_update": "2020-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "status": "COMPLETED", "last_update": "2014-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01620216", "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "status": "TERMINATED", "last_update": "2021-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779283", "title": "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia", "status": "COMPLETED", "last_update": "2020-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "status": "TERMINATED", "last_update": "2024-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TAGRAXOFUSP": { "n": 13, "n_observational": 0, "n_active": 8, "n_withdrawn": 1, "trials": [ { "nct": "NCT03113643", "title": "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05442216", "title": "Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498973", "title": "Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561152", "title": "Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07148180", "title": "A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02113982", "title": "Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2024-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02270463", "title": "SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission", "status": "TERMINATED", "last_update": "2024-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386513", "title": "Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04342962", "title": "Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05233618", "title": "Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05716009", "title": "Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML", "status": "TERMINATED", "last_update": "2026-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05720988", "title": "Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2024-03-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06456463", "title": "A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TALACOTUZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02472145", "title": "An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2019-03-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "TANDUTINIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00064584", "title": "Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)", "status": "COMPLETED", "last_update": "2009-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274248", "title": "MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2008-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00297921", "title": "A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy", "status": "WITHDRAWN", "last_update": "2013-11-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VATALANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00088231", "title": "PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP", "status": "COMPLETED", "last_update": "2012-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VENETOCLAX": { "n": 184, "n_observational": 16, "n_active": 113, "n_withdrawn": 5, "trials": [ { "nct": "NCT02416388", "title": "Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03113643", "title": "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03471260", "title": "Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03661307", "title": "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03826992", "title": "Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia", "status": "RECRUITING", "last_update": "2026-02-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04588922", "title": "Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04797767", "title": "Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms", "status": "RECRUITING", "last_update": "2026-04-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905810", "title": "Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure", "status": "RECRUITING", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988555", "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010122", "title": "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05010772", "title": "Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183035", "title": "Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05287568", "title": "CC-486 and Venetoclax for Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05360160", "title": "A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05401097", "title": "IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431257", "title": "Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling", "status": "RECRUITING", "last_update": "2022-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05506332", "title": "Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05566054", "title": "Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia", "status": "RECRUITING", "last_update": "2025-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05584761", "title": "Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML", "status": "RECRUITING", "last_update": "2022-10-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05597306", "title": "Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05736965", "title": "A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Na\u00efve Participants With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2023-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05807932", "title": "Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML", "status": "RECRUITING", "last_update": "2024-05-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05870995", "title": "Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia", "status": "RECRUITING", "last_update": "2025-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05909293", "title": "Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission", "status": "RECRUITING", "last_update": "2023-06-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06014489", "title": "A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06046313", "title": "Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS", "status": "RECRUITING", "last_update": "2024-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055621", "title": "Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE", "status": "RECRUITING", "last_update": "2026-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06152809", "title": "CIML NK Cells With Venetoclax for AML", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177067", "title": "Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06191978", "title": "A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06220162", "title": "VAC Regimen for AML Patients Who Failed to Response to VA Regimen", "status": "RECRUITING", "last_update": "2026-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06221683", "title": "Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML", "status": "RECRUITING", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06265545", "title": "Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284486", "title": "A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06301425", "title": "MRD Response-adapted Allo-HSCT for Adverse-risk AML", "status": "RECRUITING", "last_update": "2024-07-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06328179", "title": "Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.", "status": "RECRUITING", "last_update": "2024-03-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06329999", "title": "A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML", "status": "RECRUITING", "last_update": "2024-03-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06382168", "title": "DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06447090", "title": "VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT", "status": "RECRUITING", "last_update": "2024-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06501196", "title": "A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06504459", "title": "Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536010", "title": "Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML", "status": "RECRUITING", "last_update": "2024-08-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06536959", "title": "VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS", "status": "RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06571825", "title": "RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR", "status": "RECRUITING", "last_update": "2024-08-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06621199", "title": "Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML", "status": "RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06635681", "title": "Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML", "status": "RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06672146", "title": "Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06713837", "title": "IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.", "status": "RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06737523", "title": "Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML", "status": "RECRUITING", "last_update": "2025-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06746519", "title": "BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2024-12-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06783790", "title": "Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT", "status": "RECRUITING", "last_update": "2025-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810791", "title": "HVA vs IA/DA or VA in the Treatment of ND HR-AML", "status": "RECRUITING", "last_update": "2025-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06928376", "title": "A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07007312", "title": "Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059975", "title": "UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07075016", "title": "Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07078591", "title": "Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML", "status": "RECRUITING", "last_update": "2025-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07177079", "title": "High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07243483", "title": "Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia", "status": "RECRUITING", "last_update": "2026-05-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244367", "title": "Maintenance Venetoclax in AML Fit Patients", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283094", "title": "FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07304011", "title": "Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07320235", "title": "Imetelstat Combinations in Relapsed AML", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392242", "title": "A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07437950", "title": "Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07439211", "title": "Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07514936", "title": "Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07563179", "title": "Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07672262", "title": "VA Consolidation in Intermediate-Risk AML", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783100", "title": "Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01211457", "title": "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)", "status": "UNKNOWN", "last_update": "2019-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250937", "title": "Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02265731", "title": "Study Evaluating Venetoclax in Subjects With Hematological Malignancies", "status": "COMPLETED", "last_update": "2021-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02287233", "title": "A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Na\u00efve Participants With Acute Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2022-08-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02391480", "title": "A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer", "status": "COMPLETED", "last_update": "2019-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02392572", "title": "ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02397720", "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-07-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03063944", "title": "STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy", "status": "COMPLETED", "last_update": "2025-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03176277", "title": "A Study of ONO-7475 in Patients With Acute Leukemias", "status": "TERMINATED", "last_update": "2024-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03217838", "title": "Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.", "status": "TERMINATED", "last_update": "2022-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03226418", "title": "Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236857", "title": "A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies", "status": "COMPLETED", "last_update": "2023-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03404193", "title": "Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome", "status": "TERMINATED", "last_update": "2026-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455504", "title": "Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia", "status": "COMPLETED", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03466294", "title": "Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03530683", "title": "A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma", "status": "TERMINATED", "last_update": "2024-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03547115", "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML", "status": "TERMINATED", "last_update": "2026-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709758", "title": "Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Na\u00efve AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03844048", "title": "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03862157", "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03867682", "title": "Venetoclax and Lintuzumab-Ac225 in AML Patients", "status": "UNKNOWN", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03922100", "title": "Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03926624", "title": "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940352", "title": "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03955783", "title": "Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies", "status": "COMPLETED", "last_update": "2024-10-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04070768", "title": "Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04075747", "title": "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04086264", "title": "IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04102020", "title": "A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04128501", "title": "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150029", "title": "A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy", "status": "TERMINATED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04150887", "title": "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04188405", "title": "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227847", "title": "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04277442", "title": "Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278768", "title": "Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "status": "SUSPENDED", "last_update": "2026-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04336982", "title": "A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2024-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04372433", "title": "IO-202 as Monotherapy and IO-202 Plus Azacitidine \u00b1 Venetoclax in Patients in AML and CMML", "status": "COMPLETED", "last_update": "2025-02-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04424147", "title": "Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML", "status": "COMPLETED", "last_update": "2022-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04476199", "title": "Venetoclax and Decitabine Assessment in Patients (\u226560 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553692", "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers", "status": "TERMINATED", "last_update": "2025-03-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04702425", "title": "VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)", "status": "TERMINATED", "last_update": "2025-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04746235", "title": "Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04748848", "title": "A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-na\u00efve Participants Not Eligible for Intensive Therapy", "status": "TERMINATED", "last_update": "2023-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04752527", "title": "Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features", "status": "UNKNOWN", "last_update": "2021-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04763928", "title": "Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04809181", "title": "Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04822766", "title": "A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04874194", "title": "Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04904237", "title": "Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.", "status": "UNKNOWN", "last_update": "2021-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905407", "title": "Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2025-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04964505", "title": "Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia", "status": "TERMINATED", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04968015", "title": "Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04973618", "title": "Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML", "status": "WITHDRAWN", "last_update": "2021-12-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975919", "title": "Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05048615", "title": "Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML", "status": "COMPLETED", "last_update": "2023-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05053425", "title": "Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144243", "title": "Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-12", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05262465", "title": "Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML", "status": "UNKNOWN", "last_update": "2022-03-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05275439", "title": "Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361057", "title": "Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients", "status": "TERMINATED", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05433532", "title": "Study of Azacitidine\uff0cVenetoclax\uff0cand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05471700", "title": "Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2025-09-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05503355", "title": "A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML", "status": "UNKNOWN", "last_update": "2023-04-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513131", "title": "Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML", "status": "UNKNOWN", "last_update": "2022-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05520567", "title": "A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05564650", "title": "Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome", "status": "COMPLETED", "last_update": "2026-05-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583175", "title": "Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies", "status": "UNKNOWN", "last_update": "2023-11-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05628623", "title": "Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05823714", "title": "Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05833438", "title": "Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05893472", "title": "A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.", "status": "UNKNOWN", "last_update": "2023-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941585", "title": "Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2025-06-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06007911", "title": "Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2024-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06068621", "title": "Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia", "status": "COMPLETED", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06073730", "title": "Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06105658", "title": "Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML", "status": "UNKNOWN", "last_update": "2023-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06158100", "title": "Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)", "status": "TERMINATED", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06252584", "title": "Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285136", "title": "Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult", "status": "UNKNOWN", "last_update": "2024-02-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06337331", "title": "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant", "status": "WITHDRAWN", "last_update": "2024-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06429098", "title": "Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBF\u03b2::MYH11(+) AML", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06434662", "title": "Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML", "status": "UNKNOWN", "last_update": "2024-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06445907", "title": "Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06454409", "title": "Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia", "status": "SUSPENDED", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06508489", "title": "A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies", "status": "TERMINATED", "last_update": "2025-08-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06514261", "title": "Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML", "status": "SUSPENDED", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06763666", "title": "CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06770257", "title": "Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy", "status": "WITHDRAWN", "last_update": "2025-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06903702", "title": "A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia", "status": "WITHDRAWN", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07091006", "title": "Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07214064", "title": "Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation", "status": "NOT_YET_RECRUITING", "last_update": "2025-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07236931", "title": "Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Na\u00efve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells", "status": "COMPLETED", "last_update": "2026-07-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392814", "title": "Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07407660", "title": "Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423104", "title": "A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486479", "title": "Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507825", "title": "Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07537257", "title": "VEN+IDAC vs IDAC in AML", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-04-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07539818", "title": "Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604233", "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07605949", "title": "Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07635485", "title": "VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07664839", "title": "Study on the Efficacy and Safety of VA Regimen Compared to \"3+7\" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07710534", "title": "Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07726576", "title": "Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07748455", "title": "HMA-Venetoclax Induction in Newly Diagnosed AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07777471", "title": "Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07814339", "title": "Hydrochloroquinine & Decitabine With Venetoclax in AML", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "VORASIDENIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "XL-999": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00322673", "title": "Study of XL999 in Patients With Acute Myeloid Leukemia (AML)", "status": "TERMINATED", "last_update": "2010-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }